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1.  Abstract 
Microsatellite instability (MSI), i.e. length variations of repetitive DNA sequences 
(microsatellites) occurs in colorectal cancer (CRC) due to defects in the DNA 
mismatch repair (MMR) system and is a hallmark of tumors associated with hereditary 
non-polyposis colorectal cancer (HNPCC, 1 – 5% of total CRC) as well as sporadic 
CRC (15% of total CRC). Instability in coding region microsatellites (cMNR) of 
expressed genes lead to frameshift mutations and a subsequent loss of protein 
function or the translation of a truncated protein. Despite the obvious significance of 
altered glycoprotein synthesis, transport and glycosylation patterns in colorectal 
cancer, aberrant glycosylation and glycosylation pathways have not been investigated 
in MSI colorectal tumors.  
Using a bioinformatics-based approach 28 cMNR harboring candidate genes 
were identified that encode proteins of the cellular glycosylation machinery. Coding 
MNR mutation analysis in MSI CRC cell lines revealed a high mutation frequency in 
two genes: the glycoprotein transporter gene LMAN1/ERGIC53 (52%; 12/23) and the 
xylosyltransferase gene XYLT2 (35%; 8/23) that catalyzes the first step in 
proteoglycan synthesis. Apart from their occurrence in cultured cell lines these genetic 
alterations were also found at similar frequency in MSI colorectal adenomas (LMAN1: 
40%, 8/20; XYLT2: 21%, 4/19) as well as carcinomas (LMAN1: 46%, 78/170; XYLT2: 
26%, 27/105). Biallelic mutations, abrogating normal protein function, were detected in 
MSI CRC cell lines (LMAN1, XYLT2) and in primary colorectal tumors (LMAN1). 
 Biallelic mutant LMAN1 was transcribed but not translated into a stable protein 
in MSI CRC cell lines or LMAN1-mutated areas in tumors. MSI CRC cell lines with 
biallelic LMAN1 mutations behaved different to LMAN1-proficient CRC cell lines. 
LMAN1-deficient cell lines exhibited severely reduced transport and secretion of the 
LMAN1 cargo protein alpha-1-antitrypsin (A1AT), an inhibitor of angiogenesis and 
tumor growth but impaired secretion could be restored upon LMAN1 re-expression. A 
strong correlation between lower local levels of A1AT and enhanced tumor growth has 
been described. Furthermore, re-expression of LMAN1 in LMAN1-deficient LoVo cells 
led to a cell surface glycoprotein pattern different from the pattern observed on LoVo 
cells lacking LMAN1. Increased binding of PHA-L lectins to the cell surface suggested 
a glycosylation pattern known to be involved in the progression of cancer from a 
tumorigenic to a metastatic phenotype. 
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A radioactive incorporation assay with 3H-xylose also revealed changes in 
proteoglycan synthesis of a XYLT2-deficient MSI CRC cell line transiently transfected 
with a XYLT2-construct.  
Overall, two members of the cellular glycosylation machinery, a glycoprotein 
transporter and a glycosyltransferase, appear to be involved in MSI tumorigenesis. 
Genetic alterations in LMAN1 and XYLT2 mark early events already detectable in 
preneoplastic lesions. Furthermore, loss of LMAN1 and XYLT2 protein function 
changed the secretion of proteins and the cell surface glycosylation pattern. Both 
genes might influence MSI tumor progression by changing cell-cell communication and 
interactions. 
1.1  Zusammenfassung 
Mikrosatelliten-Instabilität (MSI), d.h. Längenvariationen in repetitiven DNA-Sequenzen 
(Mikrosatelliten), wird in kolorektalen Karzinomen (CRC) durch die funktionelle 
Inaktivierung eines zellulären DNA-Reparatursystems verursacht, dem sogenannten 
Mismatch-Reparatur (MMR) System. MSI ist ein Kennzeichen von MSI-Darmtumoren, die 
entweder sporadisch (15% aller Kolonkarzinome) oder im Rahmen des hereditären nicht-
polypösen Kolonkarzinoms (hereditary non-polyposis colorectal cancer HNPCC; 15% aller 
Kolonkarzinome) entstehen. Instabilität in Mikrosatelliten eines kodierenden Genabschnitts 
(cMNR) exprimierter Gene, führen zu Basenfehlpaarungen, die anschließend einen Verlust 
der Proteinfunktion oder die Entstehung verkürzter Proteine (Neopeptide) zur Folge haben. 
Eine veränderte Glykoprotein-Synthese, veränderter Transport und ein verändertes 
Glykolisierungsmuster haben eine offensichtliche Bedeutung in kolorektalen Karzinomen, 
allerdings wurden abnormale Glykosylierung und Glykosylierungswege bisher nicht in MSI 
kolorektalen Tumoren untersucht.
Unter Verwendung von Datenbank-Analysen wurden 28 Kandidatengene mit einem 
cMNR identifiziert. cMNR-Leserastermutations-Analysen bei einer Auswahl von MSI CRC 
Zellinien zeigten bei zwei Genen eine hohe Mutationsfrequenz: bei dem Glykoprotein-
Transporter Gen LMAN1/ERGIC53 (52%; 12/23) und dem Xylosyltransferase Gen XYLT2 
(35%; 8/23), das den ersten Schritt der Proteoglykan-Synthese katalysiert. Neben 
genetischen Veränderungen in MSI CRC Zellinien wurden ähnlich hohe 
Mutationsfrequenzen in MSI kolorektalen Adenomen (LMAN1: 40%, 8/20; XYLT2: 21%, 
4/19) und in MSI kolorektalen Karzinomen (LMAN1: 46%, 78/170; XYLT2: 26%, 27/105) 
beobachtet. Biallelische Mutationen, die eine veränderte Proteinfunktion zur Folge haben, 
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wurden in MSI CRC Zellinien (LMAN1, XYLT2) und in primären kolorektalen Tumoren 
(LMAN1) gefunden.  
Das biallelisch mutierte LMAN1-Gen wurde in MSI Darmkrebs-Zellinien 
transkribiert, jedoch nicht in ein stabiles Protein translatiert. Auch im Gewebe konnte eine 
biallelische LMAN1-Mutation mit einem Proteinverlust assoziiert werden. MSI 
Darmzellinien mit biallelischen LMAN1-Mutationen zeigten ein verändertes Verhalten im 
Vergleich zu LMAN1-exprimierenden MSI Darmzellinien. LMAN1-defiziente Zellinien 
wiesen einen reduzierten Transport und eine reduzierte Sekretion von einem LMAN1-
Transportprotein Alpha-1-Antitrypsin (A1AT) auf. A1AT ist ein Inhibitor der Angiogenese 
und des Tumorwachstums. Die eingeschränkte A1AT-Sekretion konnte durch Re-
Expression von LMAN1 in LMAN1-defizienten Zellinien wieder hergestellt werden. Es 
wurde gezeigt, dass ein Verlust der A1AT-Sekretion einen Wachstumsvorteil für den 
Tumor darstellt. Außerdem führte ein LMAN1-Verlust zu einem veränderten 
Glykosylierungsmuster an der Zelloberfläche von LMAN1-defizienten LoVo Zellen im 
Vergleich zu LoVo Zellen, die LMAN1 stabil exprimierten. Die vermehrte Bindung von 
PHA-L Lektinen an die Zelloberfläche war verbunden mit mehr β1-6 Verzweigungen in 
LMAN1-defizienten LoVo Zellen. β1-6 Verzweigungen sind Glykosylierungsmuster, die mit 
der Tumorprogression und der Metastasen-Entstehung in Verbindung gebracht werden. 
Der radioaktive Einbau von 3H-Xylose zeigte Veränderungen in der Proteoglykan-
synthese XYLT2-defizienter MSI-Darmzellinien, die mit einem XYLT2-Konstrukt transient 
transfiziert wurden.  
Es wurden insgesamt zwei Mitglieder der zellulären Glykosylierungsmaschinerie, 
ein Glykoproteintransporter und eine Glykosyltransferase, identifiziert, die einen Einfluss 
auf die MSI Tumorgenese haben könnten. Genetische Veränderungen in LMAN1 und 
XYLT2 sind früh auftretende Ereignisse, die bereits in prä-neoplastischen Läsionen 
nachweisbar waren. Zudem änderte der Verlust von LMAN1 und XYLT2 die Sekretion von 
Proteinen und das Glykosylierungsmuster an der Zelloberfläche. Beide Gene könnten die 
MSI Tumorprogression durch eine veränderte Zell-Zell Kommunikation oder Interaktion 
beeinflussen. 
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2. Introduction 
2.1 Colorectal Cancer 
Colorectal cancer (CRC) is the fourth most common cancer in men and the third 
most common cancer in women. Worldwide more than one million people develop 
CRC per year [Parkin et al., 2005] and 11% of total cancer deaths are related to 
CRC. The 5-year survival rate depends on tumor stage, varying from 80 – 95% for 
early stage tumors and 0 – 7% for tumors in a late stage [Weitz et al., 2005]. 
During carcinogenesis normal colonic epithelium transforms into colon adeno-
carcinomas, accompanied by a progressive accumulation of genetic alterations 
[Fearon et al., 1990; Lynch et al., 2002]. CRC is caused by the sequential 
accumulation of multiple somatic mutations affecting different cancer-related 
genes. Two major pathways lead to CRC, the chromosomal instability (CIN) 
pathway and the microsatellite instability (MSI) pathway [Lengauer et al., 1997]. 
2.2 Molecular Pathogenesis of MSI and CIN 
Although the majority of CRCs shows CIN (85%), about 15% of CRCs are 
attributable to defects in the DNA mismatch repair (MMR) system [Boland et al., 
1998; Hampel et al., 2005; Ionov et al., 1993]. MMR-deficient CRCs may develop 
sporadically or in the context of hereditary non-polyposis colorectal cancer 
(HNPCC) or Lynch syndrome [Lynch et al., 1999; Thibodeau et al., 1993]. DNA 
MMR deficiency induces a high number of mutational events characterized by 
small alterations at the nucleotide level like missense, nonsense and frameshift 
mutations [Söreide et al., 2006]. These mutations occur mainly at short repetitive 
DNA sequences, termed microsatellites, because these structures are particularly 
prone to DNA polymerase slippage during DNA replication. The resulting 
phenotype is termed high-level microsatellite instability (MSI-H). For molecular 
diagnostics of MSI-H tumors the National Cancer Institute (NCI) has recommended 
a panel of five microsatellite markers, known as Bethesda markers, which include 
two mononucleotide repeats, BAT25 and BAT26 [Boland et al., 1998], and three 
dinucleotide repeats, D2S123, D5S346 and D17S250 [Umar et al., 2004]. If two or 
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more markers are mutated, tumors are diagnosed as MSI-H. In contrast, CIN 
cancer is characterized by large chromosomal alterations like allelic losses, 
chromosomal amplifications and translocations, as well as loss of heterozygosity 
(LOH). Most CIN cancers are microsatellite stable (MSS). Tumors with CIN have 
mutations in APC, p53 and the RAS gene [Samowitz et al., 2001], whereas tumors 
with MSI show, after the initial loss of the MMR function, mutations in specific 
target genes, such as β-Catenin, transforming growth factor ß receptor II 
(TGFBR2) and activin A receptor type IIA (ACVR2A) [Kim et al., 2003; Markowitz 
et al., 1995]. Both pathways require an early step mutation of distinct genes 
followed by characteristic further mutations (Fig. 2.1).  
 
Figure 2.1 Characteristics of the two major pathways in colorectal 
cancer [Söreide et al., 2006]. About 85% of CRCs account for the 
CIN/MSS and 15% for the MSI pathway. MSS tumors show mutations in 
APC, p53 and the Ras-genes, whereas MSI tumors have mutations in the 
MMR genes and subsequently specific target genes are mutated, such as 
beta-Catenin, TGFBR2, BAX and ACVR2. 
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2.3 Microsatellite Instability (MSI) in Colorectal Cancer 
Sporadic as well as hereditary MSI-H cancers show functional inactivation of the 
MMR system. In HNPCC and Lynch syndrome tumors defects are caused by 
germline mutations in one of four MMR genes (MLH1, MSH2, MSH6 and PMS2) 
whereas in sporadic MSI-H tumors defects are attributable to epigenetic silencing 
of the MLH1 promoter [Boland et al., 1998; Ionov et al., 1993; Kane et al., 1997; 
Thibodeau et al., 1993]. In addition to MLH1 promotor methylation in sporadic MSI-
H tumors, these tumors are associated with BRAF mutations [Rajagopalan et al., 
2002]. BRAF is a serine/threonine kinase involved in the MAPK signalling pathway 
[McGivern et al., 2004]. The occurrence of MLH1 promoter hypermethylation and 
BRAF mutations distinguish HNPCC from sporadic MSI-H colon cancers. 
2.3.1 Molecular background of MSI tumors 
Microsatellites represent the most variable types of DNA sequences in the genome 
and are estimated to account for about 3% of the human genome. Microsatellites 
consist of repetitive units of different length with one to five base pairs, non-
randomly distributed throughout the human genome [Ellegren, 2004; Li et al., 
2004]. The maintenance of microsatellite stability is controlled by the MMR system, 
which is able to correct base substitutions and mismatches as well as 
insertion/deletion mutations. Figure 2.2 shows the role of the MMR system in 
maintaining the length of microsatellite sequences. Microsatellites are distributed in 
non-coding regions (intragenic or intergenic) or in coding regions. Intragenic 
regions like promoters, 3`-untranslated regions and introns can be important 
regulators of gene expression, while intergenic regions could have functions in 
chromatin organization and recombination [Shah et al., 2010]. Mutations in 
microsatellites located in coding regions of expressed genes might lead to a loss of 
protein function or the translation of truncated proteins due to frameshift mutations. 
Coding microsatellites consisting one type of nucleotide (in Fig. 2.2 an A8 repeat is 
shown) are known as mononucleotide repeats (cMNRs). Examples for genes 
frequently affected by cMNR mutations in MSI tumors are TGFBR2, ACVR2A, 
caspase 5 (CASP5) or the BCL2-associated X protein (BAX) [Duval et al., 2002]. 
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Frameshift-derived truncated proteins harbor neopeptide tails at their C-terminus 
that represent potentially antigenic epitopes capable to induce cellular and/or 
humoral immune responses [Linnebacher et al., 2001; Schwitalle et al., 2008]. It is 
generally assumed that coding microsatellite frameshift mutations in some of these 
genes provide a growth advantage to MMR-deficient cells and hence drive MSI 
tumorigenesis [Woerner et al., 2003].  
 
Figure 2.2 Role of the MMR system in maintaining microsatellite length [Kloor et al., 
2005]. MSI is associated with frameshift mutations in repetitive sequences, which can not be 
repaired by the MMR-system because of a defect either in the germline in HNPCC or by 
epigenetic silencing (MLH1-promotor) in sporadic MSI-H colorectal tumors. In MMR proficient 
cells slippages of polymerase enzymes during replication can occur either on the parental or 
daughter strand (left panel). The MMR system recognizes slippages and they are repaired. In 
MMR deficient cells insertion or deletion mutations are manifested, since they are not 
recognized by the MMR system (right panel).  
Our group has established a database of human cMNR mutations 
(www.seltarbase.org) and proposed a statistical model that allows the prediction of 
genes, that when mutated might provide a growth advantage to affected cells, 
including prediction of selective targets in human MSI-H tumorigenesis [Woerner et 
al., 2010]. The statistical model of this database is based on a sigmoid regression 
analysis aiming at the identification of genes involved in MSI carcinogenesis by 
their mutation frequency in cMNRs. There, the given cMNR length is brought into 
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correlation with the average mutation rate, revealing genes with increased or 
decreased mutation frequency. Accordingly, major efforts in MSI tumor research 
have been directed towards identifying these genes and analyzing their functional 
role. 
2.3.2 Clinicopathological characteristics of MSI tumors 
MSI colorectal tumors show a distinct clinical phenotype characterized by a poor 
differentiation [Greenson et al., 2003], strong lymphocytic infiltration [Dolcetti et al., 
1999; Smyrk et al., 2001], better prognosis and a mucinous histology [Jass, 1998]. 
Besides, MSI tumors are more frequently found in the proximal colon, are nearly 
diploid and when associated with Lynch-syndrome occur at an earlier age [Umar, 
2004]. In contrast, sporadic MSI CRC is most frequently found in older women 
[Young et al., 2001]. Furthermore MSI tumors are resistant against certain DNA-
damaging chemotherapeutic drugs, such as 5-fluorouracil (5-FU) [Carethers et al., 
1999]. In addition, colorectal cancers exhibiting MSI show a strong lymphocytic 
infiltration and a low frequency of distant metastasis [Buckowitz et al., 2005]. This 
might be attributable to enhanced immunogenicity conferred by MSI tumor specific 
neopeptides [Linnebacher et al., 2001; Schwitalle et al., 2008]. In addition to 
neopeptides, MSI-specific changes of glycopeptide expression on the cell surface 
might also contribute to the high immunogenicity in MSI tumors. 
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2.4 Eucaryotic glycosylation 
More than 5% of all mammalian genes are involved in glycosylation, encoding for 
glycosyltransferases, glycoprotein transporters or glycoprotein modifiers [Apweiler 
et al., 1999; Hebert et al., 2005; Lowe et al., 2003]. Nine monosaccharides are 
commonly found in mammals and used in the enzymatic process of glycosylation 
[Ohtsubo et al., 2006]: D-glucose (Glc), N-Acetyl-D-glucosamine (GlcNAc), D-
galactose (Gal), N-Acetyl-D-galactosamine (GalNAc), D-mannose (Man), D-xylose 
(Xyl), D-Glucuronic acid (GlcA), L-Fucose (Fuc) and sialic acid, e.g. N-
Acetylneuraminic acid (NeuAc). Conserved biosynthetic pathways provide all nine 
monosaccharides from sugars ubiquitously present in the diet. These 
monosacchrides can be covalently attached to other molecules and then 
sequentially elongated and branched creating protein-associated N- and O-
glycans, glycosaminoglycans (GAGs), and lipid-associated glycans such as 
glycosphingolipids (GSLs), as well as free glycans in the form of hyaluronan 
[Potapenko et al., 2010]. N-linked glycoproteins possess a glycosidic bond to 
asparagine residues of proteins and O-linked glycoproteins are linked to the core 
protein via serine or threonine residues. Glycans participate in multiple 
mechanisms of cellular regulation, spanning from protein quality control and 
intracellular trafficking to roles in extracellular compartments where cell-cell 
communication is modulated by adhesion, receptor activation, signal transduction 
and endocytosis (Fig. 2.3; [Ohtsubo et al., 2006]). Details on glycan function and 
the different glycan structures important for the available study are presented in 
sections 2.4.1 – 2.4.5.  
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Figure 2.3 Overview of glycan functions. Glycans produced in the secretory pathway 
possess mutilple functions in cellular processes, including protein folding, quality control and 
intracellular trafficking. Cell-cell communication is modulated by adhesion, receptor activation 
and signal transduction. ER: endoplasmic Reticulum; ERGIC: ER-Golgi intermediate 
compartment; PM: plasma membrane. 
2.4.1 N-glycosylation and the secretory pathway 
Transfer of the Dolichol-linked precursor to nascent proteins 
Oligosaccharide chains of N-gycosylated proteins are connected to the core 
protein via an asparagine residue in a distinct sequence motif. They are pre-
assembled on a lipid-based anchor in the Endoplasmic reticulum (ER). This lipid-
based anchor, the lipid-linked oligosaccharide dolicholpyrophosphate (LLO-Dol-
PP) comprises a 14-residue oligosaccharide, composed of nine Man, two GlcNAc 
and three Glc residues. The transfer is catalyzed by an oligosaccharyltransferase 
(OST) linking the 14-residue oligosaccharide en bloc to an asparagine (Asn) 
residue in the consensus sequence Asn-X-Ser/Thr (Fig. 2.4). After the covalent 
attachment of the oligosaccharide from LLO-Dol-PP to asparagine residues, a 
series of processing reactions occur, including folding and quality control [Gabius 
H-J, 2009]. 
Refolding and quality control in the ER 
The ER contains several proteins that accelerate the folding of newly synthesized 
proteins within the ER lumen. ER chaperones, the homologous lectins calnexin 
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(CX) and calreticulin (CR), bind to mono-glucosylated glycoproteins (Fig. 2.4; 
[Trombetta et al., 1998]). The removal of glucose residues, catalyzed by α-
glucosidases (Glc I, II), is associated with protein folding mechanisms and starts 
immediately after transfer from the lipid-linked oligosaccharide.  
 
Figure 2.4 Model for the quality control of glycoprotein folding [Varki et al., 2009]. 
Proteins translocating over the Sec61 transporter into the ER are N-glycosylated by the 
oligosaccharyltransferase (OST (1)). Two glucose residues are removed by the sequential 
 11
Introduction 
  
action of α-glucosidases GI and GII to generate a mono-glucosylated N-glycoprotein (2) that 
is recognized by Calnexin (CX) and/or Calreticulin (CR), associated with the protein disulfide 
isomerase ERp57 (3). Chaperones and protein disulfide isomerase (PDI) Erp57 are part of 
the N-glycoprotein quality control in the ER. Misfolded glycoproteins are re-glucosylated by 
the UDP-dependent glucosyltransferase (UGT) (4). Glycoproteins that have acquired their 
native conformation get hydrolyzed by Gl II removing the remaining glucose residue and are 
subsequently released from the lectin anchors (5). Correctly folded glycoproteins are not 
recognized by UGT and are further transported over COPII vesicles through the secretory 
pathway, in some cases glycoproteins are actively transported by LMAN1/ERGIC53 which 
serves as another checkpoint control (6). Glycoproteins remaining in misfolded 
conformations are re-translocated to the cytoplasm, where they are de-glycosylated by N-
glycanases and degraded by the proteasome (7).  
CX and CR form a complex with protein disulfide isomerase Erp57, exhibiting 
thioredoxin activity und thus helping the bound glycoprotein to build disulfide 
bonds. Properly folded glycoproteins are fully de-glucosylated by glucosidase II 
(Glc II) and the lectins CX and CR release the glycoprotein GlcNAc2Man , which is 
then packaged in COPII-coated vesicles and transferred to the Golgi [Liu et al., 
1999]. Incompletely folded glycoproteins are re-glucosylated by UDP-dependent 
glycosyltranferases (UGT) and moved out of the ER lumen for proteasomal 
degradation. UGT is both a folding sensor and a glucosyltransferase, and it is 
considered to be a decision maker for ER exit of glycoproteins. Further ER-resident 
proteins involved in quality control are ER ManI and EDEM (ER degradation-
enhancing α-mannosidase I–like protein), which trim the mannose residues as an 
indication for correctly folded glycoproteins [Hebert et al., 2005]. For example, 
glycan structures free of α-1,2-linked Man are a prerequisite for further trimming 
and elongation reactions in the Golgi apparatus. 
Transport of glycoproteins to the Golgi 
Correctly folded glycoproteins can be directly transported via lectin-mediated 
transport in CopII vesicles towards the Golgi apparatus or the transport is triggered 
by mature protein conformation-dependent mechanisms [Hauri et al., 2000; Tang 
et al., 2005]. The lectin-mediated transport also functions as a checkpoint for a 
correct folding of glycoproteins, by only binding and transporting correctly folded 
proteins. One prominent example for a lectin is ERGIC53/LMAN1, loading a subset 
of glycoproteins, e.g. coagulation factors V and VIII, cathepsins C and Z and alpha-
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1-antitrypsin (A1AT), into COPII-coated vesicles leaving the ER for the ER-Golgi 
intermediate compartment (ERGIC). 
Further Glycosylation in the Golgi 
In the Golgi apparatus glycoproteins are trimmed, elongated and branched, 
resulting in three main types of N-glycans: oligomannose N-glycans, complex N-
glycans and hybrid N-glycans, each still possessing the main core structure Asn-
GlcNAc2Man3 (Fig. 2.5). Further mannosidases and several glycosyltransferases 
are involved in trimming, elongation and branching. In addition, nucleotide sugar 
transporters import the necessary monosaccharides, like different UDP-
monosaccharides [Mendelsohn et al., 2007; Seelentag et al., 1998]. 
 
Figure 2.5 Major N-glycans present in mammals. The main N-glycans 
are oligomannose-, complex- and hybrid-N-glycans all possessing the 
common core Asn-GlcNAc2Man3. 
Enzymes that catalyze the attachment of terminal sugars 
As the N-glycan transits through the medial- and trans-Golgi, it becomes 
susceptible to glycosyltransferases increasingly localized toward the end of the 
assembly line and therefore controlling more distal structural modifications such as 
the addition of sialic acid, glucuronic acid and sulfate. Terminal sugars added by 
sialyltransferases, glucuronyltransferases and sulfotransferases present the first 
contact sites for lectins and antibodies. 
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2.4.2 O-glycosylation 
O-glycosylated proteins are linked to the polypeptide chain via serine or threonine 
residues, without requiring a consensus sequence. O-glycan biosynthesis is 
simpler than asparagine-linked oligosaccharide generation and is facilitated in the 
ER and Golgi apparatus [Van den Steen P. et al., 1998]. The initiating step is the 
addition of a monosaccharide, mainly GalNAc from a nucleotide-activated 
monosaccharide (e.g. UDP-GalNAc) to a serine or threonine residue, catalyzed by 
site-specific glycosyltransferases (e.g. GalNAc-transferases). Seven different 
linkages of O-glycans to proteins are known: O-linked GalNAc (mucin type), O-
linked GlcNAc, O-linked Gal (collagen), O-linked Man, O-linked Glc, O-linked Fuc 
and glycosaminoglycans referred to in 2.4.3.  
O-GalNAc structures are also known as mucins. Mucins are defined as cell 
surface or secreted glycoproteins less branched than most N-glycans and 
commonly with bi-antennary structures. Mucins (Fig. 2.6) are an essential part of 
the mucosal protective barrier. Secreted mucins, like MUC2, form a negatively 
charged gel which interacts with the apical membrane-anchored glycocalyx. In 
contrast, membrane bound mucins like MUC1 and MUC4 are involved in cell 
signalling. MUC2 is highly expressed in mucinous carcinomas and in early 
colorectal cancers [Allen et al., 1998; Lee et al., 2003] and it is used as a 
diagnostic marker in colorectal cancer [Lugli et al., 2007]. Eight different core 
structures are presently known for extension beyond the GalNAc-Ser/Thr linkage 
with core 1 and core 2 relatively common and core 3 and 4 showing lower 
occurrence, whereas the remaining structures are relatively rare. Each core 
determines the final structure of the extended and completed glycans formed 
through a common biosynthetic pathway [Brockhausen I., 2007; Corfield AP., 
2007; Van den Steen P. et al., 1998]. Several glycosyltransferases are involved in 
the initiating and elongating steps of O-glycan biosynthesis and act in a 
hierarchical and tissue-specific manner [Brockhausen I., 2007]. Each 
glycosyltransferase possesses a substrate specificity determining the resulting O-
glycan structures. Galactosyltransferases (GalT) and N-acetylglucosaminyl 
transferases (GlcNAcT) catalyze the core structures presented in Figure 2.6. 
Incompletely glycosylated cores are known as Tn- and T-antigens. Usually these 
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precursors are further elongated and terminally linked with fucose and sialic acid. 
Also Lewis histo blood group antigens are fucosylated and sialylated at the 
terminus of mucins (Fig. 2.8 A). Other modifications are sulfation, acetylation and 
methylation. 
 
Figure 2.6 Biosynthesis and structure of O-GalNAc structures. The 
linkage of N-acetylgalactosamine to serine or threonine to form the Tn 
antigen, catalyzed by polypeptide-N-acetylgalactosaminyltransferases 
(ppGalNAcTs), is the basis for all core structures. 
Non-mucin O-glycans regulate protein turn over by interacting with kinases and 
phosphatases [Hart et al., 2007; Yang et al., 2006], are common structures in the 
epidermal growth factor (EGF) domains and thereby involved in Notch signalling 
[Luther et al., 2009], control cell adhesion by binding to components of the 
extracellular matrix [Barresi et al., 2006], and can be a major part of the connective 
tissue in form of collagens [Liefhebber et al., 2010].
2.4.3 Glycosaminoglycans: Components of Proteoglycans 
Proteoglycans (PGs) and the attached glycosaminoglycans (GAGs) are 
components of the extracellular matrix (ECM) and the cell surface involved in many 
biological processes including extracellular matrix deposition, biomechanical 
lubrication, cell-cell interactions, tumor cell growth, viral infections or neurite 
outgrowth [Iozzo, 1998].  
PGs consist of a core protein and one or more covalently attached GAG 
chains. GAGs are linear building blocks composed of disaccharide units of an 
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amino sugar (GlcNAc or GalNAc) and an uronic acid (GlcA and IdoA). These 
disaccharide units are attached to all GAGs forming long unbranched chains of 50 
to 150 units. For three GAG types the first step in PG synthesis is the assembly of 
a tetrasaccharide linker region (serine-Xyl-Gal-Gal-Glc), in which an UDP-
xylosyltransferase (XYLT) catalyzes the initial reaction by transferring xylose from 
UDP-xylose to selected serine residues of the core protein. This reaction is 
followed by sequential action of UDP-galactosyltransferase and UDP-
glucuronyltransferase in the ER/Golgi compartments. If assembly occurs on this 
tetrasaccharide linker, heparan sulfate (HS), dermatan sulfate (DS) or chondroitin 
sulfate (CS) can be synthesized. Chondroitin sulfates differ from dermatan sulfates 
by containing iduronic acid (IdoA), which is the post-synthetic epimerization of 
glucuronic acid (GlcA) at position C5. For these three GAGs two 
xylosyltransferases XYLT1 and XYLT2, differentially expressed in human tissues, 
catalyze the rate limiting step [Götting et al., 2007].  
 
Figure 2.7 Structure of disaccharide repeat units in O-linked glycosaminoglycans 
(GAGs). GAGs consist of repeating disaccharide units composed of N-sulfated GalNAc or 
GlcNAc sugars and either an uronic acid (GlcA or IdoA) or Gal. IdoA results from postsynthetic 
epimerization of GlcA at C5. Hyaluronan lacks sulfate groups, but the rest of the GAGs contain 
sulfates at various positions. DS is distinguished from CS by the presence of iduronic acid 
(IdoA). The xylosyltransferases XYLT1 and XYLT2 present initial enzymes in proteoglycan 
synthesis of dermatan, chondroitin and heparan sulfate. Keratan sulfates are not established 
via a tetrasaccharide linker, lack uronic acids and instead consist of sulfated Gal and GlcNAc 
residues. 
 16
Introduction 
  
Another linkage without the tetrasaccharide linker is found in keratan sulfates (KS), 
which are characterized by a molecular heterogeneity. KS I molecules are N-linked 
to asparagine over GlcNAc and possess GlcNAc-Gal disaccharide units, whereas 
KS II molecules are O-linked to serine or threonine residues via GalNAc also 
possessing GlcNAc-Gal as repetitive units. Both KS types are highly sulfated. The 
fifth main type of GAGs is hyaluronan. Hyaluronan synthesis is catalyzed by 
hyaluronan synthases (HAS), each of which contain dual catalytic activities 
required for the transfer of GlcNAc and GlcA units from the corresponding 
nucleotide sugars. Figure 2.7 shows the composition of the five GAGs mentioned.  
Four main PG-structures exist in mammals, presented by extracellular 
aggregates, interstitially localized PGs, PGs associated with the basement 
membrane and membrane bound PGs. Interstitially localized extracellular large 
aggregating (hyaluronan-binding) PGs are involved in cellular attachment, cell 
proliferation and differentiation by interacting with cell surfaces and ECM molecules 
[Day, 1999; Hascall et al., 1974; Iozzo et al., 1996; Spicer et al., 2003]. 
Extracellular leucine-rich PGs, named small leucine-rich proteoglycans (SLRPs), 
interact with collagens that form the framework of the ECM. In addition, biglycan 
and decorin can bind growth factors and influence their bioactivity [Bengtsson et 
al., 1995; Iozzo, 1999; Kinsella et al., 2004; Matsushima et al., 2000]. The function 
of PGs in the basement membrane include permeability control by acting as a 
selective barrier for macromolecules, but they also serve as an adhesive matrix for 
endo- and epithelial cells and they can control the invasion of cancer cells [Iozzo, 
2005]. Cell-surface PGs, like the syndecan family act as co-receptors, by 
immobilizing ligands, presenting them to a specific receptor, and preventing their 
degradation. In addition they mediate the adhesion of skeleton structures and 
facilitate focal adhesions. Their ectodomain can be shed from the cell surface by 
enzymatic cleavage mediated by endoglyosidic enzymes, like HS-specific 
endoglycosidases. HS-degradation in mammalian cells is mediated by a single 
dominant endoglycosidase, named heparanase [Parish et al., 2001]. Shed 
syndecans have been found in serum and in body fluids during wound healing and 
cancer, probably altering the integrity and functional state of tissues and providing 
a mechanism by which cells can respond rapidly to changes in the extracellular 
environment [Vlodavsky et al., 2001]. Enzymatic degradation of HS is, therefore, 
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likely to be involved in fundamental biological phenomena, ranging from 
pregnancy, morphogenesis, and development to inflammation, angiogenesis, and 
cancer metastasis [Bernfield et al., 1992]. 
2.4.4 How, where and why are proteins glycosylated? 
After protein synthesis, proteins are post-translationally modified in the ER and 
Golgi apparatus. Polypeptide chains are trimmed, serine, threonine, or tyrosin 
residues are phosphorylated or sulfated, and oligosaccharides can be added. 
Many extracellular proteins in the serum, urine, saliva and lymph as well as integral 
proteins and proteins on the extracellular membrane are glycosylated. Length, 
charge and sequence of sugar chains depend on the species, tissue, age and the 
condition of the organism, like pregnancy, disease or cancer. The glycosylation of 
proteins has various functions: glycosylation protects proteins from proteolytic 
digest, can change the affinity of receptor-ligand interactions and the activity of 
certain hormones and enzymes. It can serve as a signal in intracellular transport 
and the interaction of sugar chains in proteins of extracellular matrices and 
membranes, regulating migration and distribution of cells in the organism (Kobata 
et al., 1992). 
A specific glycoprotein leaving the Golgi apparatus may carry different types 
of glycans depending on the situation and the different purposes to fulfill. The 
complexity of the enzymatic reactions and the topological order of the enzymes 
involved along the assembly line of glycoprotein synthesis determine the display of 
glycans on the cell surface and the sorting of glycosylated proteins. N-glycan 
structures are found on cell receptors for signalling and interaction processes (e.g. 
EGFR, FGFR, PDGFR and integrin/cadherin induced signaling), on immunological 
proteins (immune globulines, NK cells) and N-glycans can form a molecular lattice 
with galectins, opposing glycoprotein endocytosis. N-glycans are thereby involved 
in several cellular processes like cell adhesion, self/nonself recognition, molecular 
trafficking and clearance, receptor activation and endocytosis [Ohtsubo et al., 
2006]. O-glycans, as well as GAGs in proteoglycans, possess physical and 
structural functions as protective barriers (e.g. mucins) or control cell-adhesion and 
cell signalling by mediating cell-cell and cell-matrix interactions. Furthermore they 
are components of the extracellular matrix (ECM) and the cell surface. [Hart et al., 
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2007; Liefhebber et al., 2010; Luther et al., 2009; Parish et al., 2001; Spicer et al., 
2003; Yang et al., 2006]. Overall, with these several functions in fundamental 
biological processes alterations in these structures could lead to abnormalities, 
which are also considered to be functional in tumorigenesis. 
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2.5 Glycans involved in tumorigenesis  
Altered glycosylation is a universal feature of cancer cells, and certain glycan 
structures are well-known markers for tumor progression. Glycosylation plays a 
principal role in a number of cellular processes of key importance for 
tumorigenesis. Enzymes and transporters mediating growth receptor regulation, 
growth factor modulation, cell-cell adhesion, immune system modulation, cell 
motility or the adhesion to endothelium are of great impact for normal cell behavior 
[Potapenko et al., 2010]. If any of these important key players is mutated, normal 
cell behavior is changed, which may affect adhesion properties and cell-cell 
signalling as well as modulate the immune response.  
2.5.1 N-glycans and cancer 
Three main types of N-glycans, oligomannose N-glycans, complex N-glycans and 
hybrid N-glycans, exist which are further trimmed, elongated and branched by 
mannosidases and glycosyltransferases. To yield complex tri- and tetra-antennary 
N-glycans additional branches can be initiated by GlcNAcT-IV (MGAT4) and by 
GlcNAcT-V (MGAT5). GlcNAc-branched complex-type N-glycans are found among 
others on glycoprotein receptors. A striking example of such glycan receptor-
mediated function is the binding of galectins to MGAT5-modified N-glycans at the 
T-cell receptor reduced T-cell activation and autoimmunity by preventing T-cell 
recruitment to antigen presentation sites [Demetriou et al., 2001]. The interaction 
between galectins and branched N-glycans produces a thermodynamically stable 
array of galectins and glycoproteins at the cell surface, called the galectin lattice 
(Fig. 2.8; [Demetriou et al., 2001]). Expression of MGAT5 and branched N-glycans 
are increased in various carcinomas [Dennis et al., 1999], while galectin-3 
expression is associated with tumor progression and cancer metastasis in several 
tumor types [Takenaka et al., 2004]. Cell lines with increased MGAT5 expression 
show an increased frequency of metastasis in animal models [Goetz, 2009]. The 
plant lectin L-phytohemagglutinin (PHA-L) emerged as a marker for preferentially 
recognizing branched N-glycans bearing the β1-6 branched GlcNAcT-V product in 
tumor tissues [Przybylo et al., 2008]. 
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Figure 2.8 N- and O-glycans involved in tumor progression. A. Complex N-glycans 
contain two or more antennae. The O-glycans shown are of the O-GalNAc type, also known 
as mucins. Lewis antigens are carbohydrate determinants composed of four sugars in specific 
linkage to one another, and are commonly over-expressed on tumor-cell mucins. Tn and STn 
are tumor antigens that consist of truncated/incompleted O-linked chains. In many tumors 
their accumulation correlates with invasion. B. shows the involvement of branched complex N-
glycans, generated by the enzyme MGAT5. Galectins bind branched complex N-glycans on 
glycoprotein receptors. Together they build the galectin lattice. Expression of MGAT5 and 
branched N-glycans is increased in various carcinomas [Fuster et al., 2005; Goetz, 2009]. 
2.5.2 O-glycans and cancer 
O-linked glycans, namely mucins, regulate adhesion and modulate immune 
response. The synthesis of core structures 1 – 4, and rare core structures 5 – 8, is 
initiated by GalNAc transferases transferring GalNAc to either a serine or a 
threonine of the core protein [Ten Hagen et al., 2003]. Mucins are produced by 
normal mammalian cells and contain a mixture of extended core 2 structures. 
Mucins play a role in invasion, metastasis and protection [Hollingsworth et al., 
2004]. Cancer cells frequently synthesize mucins with incomplete oligosaccharide 
chains which are often sialylated, resulting in aberrant core 1 structures. The 
synthesized structures are called Tn-antigen (GalNAc-α1-O-serine/threonine) and 
STn-antigen (Siaα2-6GalNAc-α1-O-serine/threonine), which are markers for poorly 
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differentiated adenocarcinoma and their increased occurrence is associated with 
advanced colon cancer [Itzkowitz et al., 1990]. Changes in these mucins influence 
growth and survival of the cell, because potential ligands responsible for 
interactions between cancer cells and their environment are changed. Selectins, 
which mediate cell adhesion by acting as glycoprotein receptors, were reported to 
bind mainly carcinoma mucins [Aychek et al., 2008]. In addition, selectin binding to 
cell surface-bound mucins may also transmit signals into cancer cells during 
cancer progression, e.g. by enhancing growth factor receptor signalling 
[Hollingsworth et al., 2004; Kufe, 2009]. 
2.5.3 Proteoglycans and cancer 
Heparan sulfates (HS) are a central part of the ECM and play an important role in 
many biological processes [Vlodavsky et al., 2001]. As mentioned in section 2.4.3, 
enzymatic degradation of HS in syndecan-molecules of the ECM is involved in 
fundamental biological processes, ranging from pregnancy, morphogenesis, and 
development to inflammation, angiogenesis, and cancer metastasis [Bernfield et al., 
1992]. The HS-specific endoglycosidase, named heparanase, showed an increased 
expression in human malignancies compared with the corresponding normal tissue 
[McKenzie et al., 2000]. Tumor angiogenesis can be processed by the remodelling 
of the vascular system (Fig. 2.9). The importance of mammalian heparanase in 
vascular remodelling was demonstrated [Zcharia et al., 2004]. The cleavage of 
heparan sulfates in the ECM might provide pro-angiogenic factors, including growth 
factors (VEGF, FGF2, PDGF and TGFß), that in addition bind heparan sulfates, 
thereby promoting tumor angiogenesis [Bogenrieder et al., 2003; Jiang et al., 2003]. 
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Figure 2.9 Proteoglycans involved in tumor angiogenesis. Tumor 
angiogenesis is required for tumor growth and the possibility of the tumor 
to metastasize. Heparan sulfate on the cell surface (ECM) facilitates 
growth-factor binding and activation of endothelia glycoprotein receptors 
[Fuster et al., 2005]. 
2.5.4 Glycans and MSI CRC 
The previous sections gave an overview on the important and various functions of 
several glycoproteins and their involvement in tumorigenesis. In particular, 
glycosylation of proteins which is mediated by a framework of genes is changed in 
many tumor entities, affecting important cellular processes. For sporadic MSI tumors 
increased MUC2 gene expression was reported and changed MUC structures may 
be an important step in the neoplastic molecular pathway of colon tumors [Pastrello 
et al., 2005]. In contrast, MUC2 loss was reported to be an appropriate prognostic 
marker in MSI tumor progression [Lugli et al., 2007]. Oligonucleotide microarray 
analysis of MSI-H and MSS colorectal carcinomas showed that expression profiles 
can be distinguished in both cancers [Kim et al., 2004]. For MSI-H carcinomas three 
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genes with an involvement in glycosylation were shown to be upregulated, SIAT4B, 
B4GALT1 and GALNT5. Apart from these preliminary data on glycosylation genes in 
MSI CRC, aberreant glycosylation and glycosylation pathways have not been 
investigated in MSI-H tumors. Detailed analyses of glycosylation genes and their 
involvement in MSI tumorigenesis will be part of this thesis. The specific aims are 
discussed in the next section.
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2.6 Aims of the work 
The accumulation of tumor-promoting coding microsatellite mutations is considered 
to be the driving force in MSI colorectal carcinogenesis [Furlan et al., 2002; 
Woerner et al., 2001]. Frameshift mutations in coding regions lead to a loss of 
protein function or the mutated protein is translated with a newly synthesized 
carboxy-terminal neopeptide [Linnebacher et al., 2001; Schwitalle et al., 2008]. The 
strong immune response in MSI cancers could be explained by these tumor-
specific neopeptides. However, also deregulated protein glycosylation in cancer 
cells might lead to the formation of highly immunogenic tumor specific 
glycoantigens, mainly located on the cell surface. Besides acting as tumor antigens 
it is likely that they are actively involved in tumor progression and metastasis. 
Therefore detection of defined carbohydrate and/or glycoprotein tumor antigens 
and the identification of abnormal glycosylation pathways in tumors is of special 
interest for improved diagnostic and therapeutic strategies, as well as for better 
understanding of MSI tumorigenesis [Dube et al., 2005; Dwek et al., 2004; Vlad et 
al., 2004; Patsos et al., 2009]. 
The present thesis aimed at the identification and characterization of cMNR 
harboring genes encoding proteins of the cellular glycosylation machinery with 
emphasis on frameshift mutations resulting in abberant cell surface presentation or 
secretion of glycoproteins. Building on that, these alterations in glycoprotein 
structures or secretion patterns should be further analyzed. The final aim was to 
establish a basis for the detection of MSI cell-specific glycosylation patterns that 
can be used for the development of novel diagnostic and therapeutic strategies for 
MSI tumors, and for the detection of changes relevant to MSI tumorigenesis. To 
reach these aims, frameshift mutation analysis and functional analysis were 
combined with biochemical methods. The specific aims of this study are: 
 
I. The identification of cMNR harboring candidate genes encoding proteins 
of the glycosylation machinery and to determine their mutation frequency 
in MSI CRC cell lines, adenomas and carcinomas.  
II. The analysis of protein expression of candidate genes identified in I. in 
MSI CRC cell lines and primary tissues. 
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III. The evaluation of the function of candidate genes mutationally 
inactivated in MSI CRC cell lines by using methods, such as metabolic 
labelling and cell surface staining. 
IV. To perform protein expression and purification experiments to generate 
new tools for the identification of relevant interaction partners of 
candidate genes with an involvement in MSI tumorigenesis. 
 
Overall, frameshift mutation analyses as well as expression and functional 
analyses should reveal novel insights into candidate genes presumably involved in 
MSI tumorigenesis. In addition, MSI tumor-specific glycosylation patterns 
potentially provide the basis for novel diagnostic and therapeutic approaches. 
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3.  Results 
3.1  Glycogenes involved in MSI-H colorectal 
tumorigenesis 
Despite the obvious significance of altered glycoprotein synthesis, transport and 
secretion in CRC, aberrant glycosylation and glycosylation pathways have not been 
investigated in MSI-H colorectal tumors. In order to identify cMNR-harboring genes, 
encoding components of the cellular glycosylation machinery candidate genes were 
selected by a bioinformatics-based approach. Database analysis and specific 
selection criteria such as subcellular localization, cMNR length, and involvement in 
glycosylation were applied to pre-select candidate genes. 
Potential candidates were selected from three databases: for the first 
database a filter for the subcellular localization (Locate database) of candidate genes 
was used, second the MNR_ensembl database was filtered by limiting human 
cMNRs to seven and more basepairs and third the SelTarbase was filtered for 
candidates which were already analysed, e.g. the previously investigated genes 
TGFBR2, ACVR2, AIM2 and UPF3A. For details on database analysis see section 
6.5. These three databases revealed 431 genes and a final short list selection (Filter 
4) was based on literature data showing a function of the corresponding gene 
product in glycan synthesis, modification or transport (Figure 3.1A). As a result, 28 
candidate genes were selected for subsequent analyses. 
DNA frameshift mutation profiles of these 28 candidate genes with 32 cMNRs 
were determined on a panel of 48 CRC cell lines (MSS, n = 25, MSI-H, n = 23; Fig. 
3.2). Mutation frequencies ranged from 0 to 52%, whereas no frameshift mutations in 
any of these genes were detectable in MSS CRC cell lines. For XYLT2 and LMAN1 
even biallelic mutations were found and both genes appeared as positively selected 
target genes according to the statistical model described in 2.3.1 (Fig. 3.1 B). To 
exclude that the observed frequencies of selected genes were restricted to cultured 
cells, mutation profiles were also determined for at least 50 MSI-H colorectal tumors 
(Fig. 3.3). For this analysis only those candidate genes frequently mutated (≥ 10%) in 
the cell culture panel were selected. An equal number of MSS colorectal tumors and 
blood samples from healthy donors served as controls. 
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Figure 3.1 Strategy for the identification of candidate genes and the 
statistical model for the predicition of MSI-H target genes. A. Four filters 
for the selection of candidate genes were applied to three databases. Filters 
selected by location (1), cMNR-length (2) already analysed cMNRs (3), as 
well as by literature-based involvement in glycosylation (4). For details see 
methods. B. Regression analysis of cMNR mutations in MSI-H CRC cell 
lines. LMAN1 and XYLT2 analysed as genes involved in the glycosylation 
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machinery seem to be MSI-H target genes. Green dots represent putative 
positively selected targets. 
 
Figure 3.2 Frameshift mutation analysis of candidate glycogenes in 
MSI-H CRC cell lines. Different wildtype lengths of individual cMNRs are 
indicated by bar color (white, n = 7; gray, n = 8; black, n = 9). Overall 
mutation frequencies are depicted. Three genes (*) contained more than one 
cMNR (B4GALNT4, 3 G7; ALG12, 2 C7; PIGZ, 1 C7 and 1 G7). 
Three genes were found to be frequently mutated (≥ 10%) in MSI-H colorectal 
tumors, namely LMAN1 (46%), XYLT2 (26%) and B4GALNT4 (23%). This finding 
was corroborated by extended analysis of these 3 genes on an additional panel of 
MSI-H tumors (LMAN1 n = 120, XYLT2 n = 55, B4GALNT4 n = 43). Besides, XYLT2 
and LMAN1 harbored biallelic mutations in two (XYLT2: 2/23; 8.6%) and four 
(LMAN1: 4/23; 17,4%) MSI-H CRC cell lines investigated. Biallelic mutations imply a 
complete knockout or a dysfunction for the protein. Because cell lines with biallelic 
mutations represent powerful tools for further research the two genes LMAN1, a 
glycoprotein transporter and XYLT2 (Xylosyltransferase 2), an initial enzyme in 
proteoglycane synthesis were selected for further analysis. 
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Figure 3.3 Frameshift mutation frequencies of a subset of candidate 
glycogenes in primary MSI-H CRCs. Gene-specific mutation data were 
obtained by analyzing 50 MSI-H carcinomas except for LMAN1 (n = 170 
tumors), XYLT2 (n = 105 tumors), and B4GALNT4 (n = 93 tumors). Bar 
characteristics (asterisks, shading) as described in Fig. 3.2. 
To evaluate if LMAN1 and XYLT2 mutations were early events in MSI-H 
tumorigenesis a subset of 20 MSI-H colorectal adenomas was analyzed. A significant 
fraction of these adenomas (LMAN1 40%, 8 of 20; XYLT2 21%, 4 of 19) showed 
cMNR frameshift mutations. LMAN1 gene mutation status was compared with the 
UICC tumor stages for MSI-H CRCs and a comparison of sporadic and HNPCC MSI-
H cancers was examined, but no significant correlation to any UICC stage could be 
made (data not shown). LMAN1 mutations appeared to be more frequently observed 
in HNPCC compared to sporadic MSI-H colorectal carcinomas. However, the low 
number of cases which were available for these analyses revealed no significant 
differences. 
Overall, it was determined that two genes involved in the glycosylation 
machinery were frequently and also biallelically mutated in MSI-H CRCs. These 
genes might play a role in MSI-H tumorigenesis. The following sections will present 
detailed analyses of LMAN1 and XYLT2. 
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3.2  LMAN1 mutational inactivation in MSI-H colorectal 
tumorigenesis 
3.2.1 LMAN1 transcript is present, but LMAN1 protein is not 
detectable in biallelic-mutated cells 
To understand the nature of the genetic defects observed in MSI-H CRC cells and 
tumors (3.1) LMAN1 expression was analyzed at the transcript and protein level. For 
the analysis of LMAN1 transcription cDNAs from 23 MSI-H CRC cell lines, one MSS 
cell line (SW948) and normal human colonic mucosa were used. LMAN1 mRNA was 
found to be expressed in all samples, including cell lines harboring mono- or biallelic 
LMAN1 cMNR frameshift mutations and was also found in normal colon tissue (Fig. 
3.4A).  
To verify the transcription data at the translational level, Western blot analysis 
with an LMAN1-specific antibody was performed on a panel of LMAN1-mutated and 
LMAN1-wild type cells. LMAN1 was detectable in all 19 heterozygously mutated cell 
lines and in cells expressing wildtype LMAN1, whereas four cell lines Colo60H, LoVo, 
HDC9 and Vaco 6, harboring biallelic LMAN1 mutations, lacked LMAN1 protein 
expression (Fig. 3.4B). Although the LMAN1-antibody recognizes an N-terminal 
epitope, no truncated protein (expected size of 36 kDa) was detected in cell lines with 
mono- or biallelic cMNR frameshift mutations. LMAN1 mutated transcript is predicted 
to be NMD-sensitive with a premature termination codon occurring more than 55 
base pairs upstream of the last exon-exon border (explained in 4.2.2) and resulting in 
the degradation of the transcript. However, the transcript could be detected by RT-
PCR in all mutated cell lines.  
Expression analysis showed that biallelically LMAN1-mutated cell lines were 
able to transcribe but not to translate a mutated LMAN1. The identification of LMAN1-
deficient cell lines provides a valuable tool for studying the functional consequences 
of LMAN1 inactivation. 
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Figure 3.4 LMAN1 expression in MSI-H CRC cell lines. A. RT-PCR analysis of LMAN1 
expression in CRC cell lines with homozygous wild-type (+/+), homozygous mutant (−/−), or 
heterozygous (+/−) cMNR status. The expected PCR fragment of 122 bp could be amplified 
from cDNA of normal human colon, 1 MSS cell line (SW948), and all MSI-H CRC cell lines. 
GAPDH was amplified as a cDNA quality control. B. A single band of 53 kDa corresponding to 
the LMAN1 protein was detected in MSI-H and MSS CRC cell lines harboring homozygous 
wild-type or heterozygous cMNR in MSI-H and MSS cell lines. MSI-H CRC cell lines with 
biallelic cMNR frameshift mutations lacked LMAN1 protein expression. No truncated LMAN1 
protein (expected size, ~36 kDa) was visible in heterozygously or homozygously mutated cell 
lines. Molecular weight marker bands are depicted. Actin served as loading control. 
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3.2.2 Complete or partial loss of LMAN1 protein expression in MSI-H 
CRC tumors 
In cultured cells, LMAN1 protein loss was observed as a consequence of biallelical 
LMAN1 mutations (see Fig. 3.4B). In order to investigate the expression of LMAN1 in 
primary tissues we performed immunohistochemical analysis on a set of 50 MSI-H 
colorectal carcinomas. 
 
Figure 3.5 Immunohistochemical detection of LMAN1 protein in MSI-H 
colorectal tumors. Representative immunohistochemical staining patterns 
of MSI-H colorectal tumors using an LMAN1-specific antibody. LMAN1 was 
visualized by using 3,3`-beta-diaminobenzidine (brown). Tumor sections 
were counterstained with hematoxylin (blue). In all tumor sections, positive 
LMAN1 staining of stromal cells and tumor-infiltrating lymphocytes served as 
control. Scale bars: 100 µm in all panels. A. Four carcinomas that display 
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either complete or partial loss of LMAN1 expression, sometimes comprising 
areas with a heterogeneous speckled pattern. B. In two MSI-H colorectal 
adenomas, complete loss (left) as well as focally restricted loss of LMAN1 
expression was observed (right). Arrow, crypt with mixed staining. 
A significant fraction of these carcinomas showed either local (38%; 19/50) or 
complete loss (6%; 3/50) of LMAN1 expression. Representative examples of this 
heterogeneous staining pattern are presented in Figure 3.5. Moreover, when a small 
number of MSI-H adenomas were subjected to immunohistochemical staining, a 
similar pattern (Fig. 3.5B) was observed. Regional loss of LMAN1 expression might 
be attributable to biallelic mutational inactivation of the LMAN1 gene in specific tumor 
areas. In order to address this issue, DNA from areas with or without LMAN1 
expression was isolated by regional microdissection on selected MSI-H carcinomas 
(n = 4) and MSI-H adenomas (n = 3).  
 
Figure 3.6 Molecular analysis of intratumoral LMAN1-deficient areas. Regional 
microdissection of a colorectal carcinoma. Non-malignant colorectal epithelium strongly 
expressing LMAN1 showed only LMAN1 cMNR wild-type allele peaks (+/+) in 
electropherograms of fragment length analysis. Tumor areas that have retained LMAN1 
staining but with reduced staining intensity compared with non-tumorous stromal cells exhibited 
an additional peak in frameshift analysis corresponding to a heterozygous state wildtype and 
one bp deletion at the LMAN1 coding microsatellite (+/−). Tumor areas completely lacking 
LMAN1 staining only displayed homozygous mutant allele and peak pattern (−/−). Arrow 
indicates wild type LMAN1 and should relieve the shifts of one allele (+/−) or both alleles (−/−), 
respectively. 
DNA frameshift mutation analysis revealed biallelic cMNR frameshift mutations in the 
LMAN1 gene in tumor areas and concomitant loss of LMAN1 protein expression (Fig 
3.6 right panel). Areas with decreased LMAN1 expression compared to normal tissue 
(Fig 3.6 left panel) showed heterozygous mutations for LMAN1 (Fig 3.6 middle 
panel). Correlation between protein expression and frameshift mutation pattern was 
also observed in adenomas (data not shown). 
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From these results it can be concluded that primary MSI-H colorectal tumors 
frequently show heterogeneous LMAN1 expression abnormalities caused by regional 
biallelic cMNR frameshift mutations in MSI-H tumor cells. In addition, the occurrence 
of LMAN1 mutations in preneoplastic lesions marks an early event during MSI 
tumorigenesis.
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3.3  LMAN1 expression changes the phenotype in MSI-H 
CRC cells 
It is reasonable to assume that inactivating mutations or altered expression of 
LMAN1 cause changes in the transport of glycosylated proteins that follow the 
secretory pathway. Changes in the glycoprotein export might change the cell’s 
phenotype. In order to identify phenotypical changes in MSI-H CRC cells LMAN1 full-
length cDNA was expressed in LMAN1-deficient MSI-H CRC cells. Stable clones 
were checked for cell viability and LMAN1 expression and subsequently analyzed for 
phenotypic changes. Glycoprotein profiling on the cell surface was performed by 
Lectin-FACS analysis. 
3.3.1 Stable LMAN1 expression does not change cell viability and 
growth 
For stable expression of LMAN1 a LMAN1 clone was established by transfecting 
LMAN1 cDNA into LoVo cells. LoVo cells show a biallelic mutation in the cMNR of 
the LMAN1 gene (A9 ? A8). The expression of LMAN1 was checked by Western 
blot analysis. Compared to an MSI-H CRC cell line endogenously expressing LMAN1 
(Co115), the expression intensity was weaker in one LMAN1-transfected LoVo clone 
(Fig. 3.7), while all other clones checked after freeze/thaw cycles lacked LMAN1 
expression. This LMAN1-transfected LoVo clone permanently expressed the LMAN1 
gene.  
 
Figure 3.7 Western blot analysis of stably transfected LoVo cells 
constitutively expressing LMAN1 protein. A single band of 53 kDa 
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corresponding to the LMAN1 protein was detected in a MSI-H CRC cell line 
endogenously expressing LMAN1 (Co115) and in LoVo cells constitutively 
expressing LMAN1. No protein was detected in LoVo cells deficient for 
LMAN1 and in mock-transfected LoVo cells expressing the empty vector 
control (pcDNA3.1). Molecular weight marker bands are depicted. Probing 
with an anti-actin antibody served as loading control. 
LoVo cells stably transfected with LMAN1 (LMAN1-transfected LoVo cells) were 
characterized by cell viability and compared to LoVo cells stably transfected with the 
empty vector pcDNA3.1 (mock-transfected LoVo cells). LMAN1-transfected LoVo 
cells did not differ from mock-transfected LoVo cells in a proliferation assay (Fig. 3.8), 
thus no difference in cell viability was observed. In addition, LMAN1-transfected LoVo 
cells showed no growth advantage or disadvantage compared to the parental line 
(LoVo) or to mock-transfected LoVo cells.  
 
Figure 3.8 Cell Proliferation Assay of stably transfected LoVo cells. 
3000 LoVo-, mock-transfected and LMAN1-transfected LoVo-cells were 
sowed per well of a 96-well plate and MTS/formazan solution was added 
after 1, 2 and 5 days. The MTS tetrazolium compound is bio-reduced by cells 
into a colored formazan product that is soluble in tissue culture medium. 
Absorbance was measured at 485 nm. Formazan is directly proportional to 
the number of living cells in culture. Values represent triplets for each cell line 
and day. Error bars represent standard deviations. 
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3.3.2 LMAN1 expression changes the glycan profile on the cell 
surface 
LMAN1 is a mannose-specific lectin and reconstituted LMAN1-expression could 
change the cell surface pattern by the transport of specific LMAN1-cargo proteins 
that function as glycoproteins on the cell surface. To compare the cell surface pattern 
in LMAN1-deficient and LMAN1-reconstituted LoVo cells, Lectin-FACS analysis was 
performed. The experiment was established using LMAN1-transfected LoVo cells or 
mock-transfected LoVo cells (3.3.1). A selection of biotinylated plant lectins, specific 
for distinct building blocks of human glycans was used (Tab. 3.1) with ConA, LEA, 
PSA and PHA-E specifically detecting mannose-harboring structures (Tab. 3.2 in 
bold).  
Table 3.1 Lectin panel for glycan profiling of cell surfaces and effect of LMAN1 expression 
Plant name Acronym LMAN1 effectin % Oligosaccharide 
Canavalia 
ensiformis  ConA no change 
GlcNAcβ2Manα6(GlcNAcβ2Manα3)Manβ4Gl
cNAc 
Lycopersicon 
esculentum  LEA no change 
Core and stem regions of high-mannose-
type N-glycan 
Pisum sativum PSA + 14,6 (p-value:0,281)
N-Glycan binding enhanced by core 
fucosylation 
Phaseolus vulgaris 
erythroagglutinin  PHA-E no change 
Bisected complex-type Nglycans: 
Galβ4GlcNAcβ2 Manα6 (GlcNAcβ2Manα3) 
(GlcNAcβ4)Manβ4GlcNAc 
Phaseolus vulgaris 
leukoagglutinin  PHA-L 
− 22,2 
(p-value:0,057)
Tetra- and triantennary N-glycans with β6-
branching 
Maackia 
amurensis I  MAA-I no change 
Neu5Acα3Galβ4GlcNAc/Glc, 3 -sulfation 
tolerated 
Artocarpus 
integrifolia  JAC 
+ 28,5 
(p-value:0,125) Galβ3GalNAcα, α3-sialylation tolerated 
Triticum vulgare WGA + 19,9 (p-value:0,267) (GlcNAc)n, Galβ4GlcNAcβ6Gal 
Sambucus nigra  SNA no change Neu5Acα6Gal/GalNAc, clustered Tn antigen 
Viscum album  VAA no change Galβ2(3)Gal, Galα3(4)Gal, Galβ3(4)GlcNAc without/with α2,6-sialylation, Fucα2Gal 
Arachis hypogaea  PNA no change Galβ3GalNAcα 
Lectin panel used to identify phenotypic changes on the cell surface of mock-transfected and 
LMAN1-transfected LoVo cells. Plant name, acronym and oligosaccharide specificity for each 
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lectin are given. The column “LMAN1 effect” shows the lectin binding change upon LMAN1 
expression. Mean fluorescence intensities of LMAN1-transfected LoVo cells were compared to 
mock-transfected LoVo cells. (+) for increased and (–) for decreased binding. Values presented 
are the mean of the difference in mean fluorescence of four independent experiments. P-values 
are indicated. 
Both, the percentage of positive cells and mean fluorescence intensity were 
measured for comparison. For LMAN1-transfected LoVo cells a significant decrease 
in cell surface PHA-L lectin binding was observed. Changes in lectin binding were 
also detected for PSA, Jacalin and WGA, but this trend remained statistically 
insignificant. There were no changes on the cell surface for any other lectins 
measured (Table 3.1). Figure 3.9 represents the cell surface profiling of the lectins 
PHA-L and jacalin (JAC). Interestingly, changes on the cell surface were observed 
upon LMAN1 reconstitution, but no mannose-specific lectin showed changes upon 
LMAN1 re-expression in stable LoVo cells. With PHA-L detecting tetra- and tri-
antennary N-glycans and jacalin specific for Galβ3GalNAcα-structures (galactosyl (ß-
(1,3) N-acetylgalactosamine), a N-glycosidically lectin and an O-glycosidically lectin 
showed the highest effects after LMAN1 reconstitution. 
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Figure 3.9 FACS histograms and Box & Whisker Plots for lectins PHA-L and JAC. A. 
Semilogarithmic representation of fluorescent surface staining of LoVo cells. Cells were treated 
with biotinylated lectins and subsequently incubated with Streptavidin-Phycoerithrin (PE) as 
fluorescent dye. Histograms represent the fluorescence intensity for both mock-transfected 
LoVo cells (LoVo pcDNA3.1; light grey) and LMAN1-transfected LoVo cells (LoVo LMAN1; dark 
grey). The values for the percentage of positive cells and the mean are given. JAC lectin 
binding was increased upon LMAN1 expression whereas PHA-L abundance on the cell surface 
decreased upon LMAN1 expression. Experiments represent data from one out of four 
independent measurements. B. Box & Whisker Plots representing the PHA-L and JAC mean 
fluorescence values of four independent experiments. Both lectins showed effects upon LMAN1 
reconstitution. Mean fluorescence, standard deviation and standard error are presented within 
the Box & Whisker Plot.
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3.4  Analyses of LMAN1 cargo proteins relevant to MSI-H 
CRC 
As a transporter for mannose-harboring glycoproteins, LMAN1 plays an important 
role in the secretory pathway enabling the transport from the ER to the Golgi via the 
ERGIC (ER-Golgi Intermediate Compartment). Several LMAN1 cargo proteins are 
known, including the serine protease inhibitor alpha-1-antitrypsin (A1AT), the 
lysosomal glycoproteins cathepsin C and Z as well as the blood coagulation factors V 
and VIII [Nyfeler et al., 2008; Appenzeller et al., 1999; Moussalli et al., 1999; 
Vollenweider et al., 1998]. To get more insight into LMAN1`s role as a cargo protein 
receptor, different strategies for the identification and characterization of LMAN1 
cargo proteins were performed.  
3.4.1 Alpha-1-antitrypsin secretion is impaired in LMAN1 deficient 
cells 
A1AT is an inhibitor of several serine proteases involved in inhibiting angiogenesis 
and tumor growth [Huang et al., 2004]. A1AT also exhibits important regulatory and 
anti-inflammatory roles [Kalsheker, 2009]. Using an A1AT-specific ELISA, A1AT 
secretion in LMAN1-deficient and -proficient MSI-H CRC cells as well as LMAN1-
transfected cells and mock-transfected cells was analyzed. Significantly decreased 
levels of A1AT were measured in a conditioned medium of LMAN1 deficient cells (~ 5 
µg/L) compared to a conditioned medium of LMAN1 proficient cells (~ 15 µg/L, 
Fig.3.10 A). To test whether LMAN1 re-expression could overcome this secretion 
defect, LMAN1-deficient Colo60H cells were transiently transfected with LMAN1-
cDNA. A 10-fold increase in A1AT concentration in the medium of Colo60H 
overexpressing LMAN1 compared with the empty vector control was observed (Fig. 
3.10B). RT-PCR analysis revealed A1AT transcription in all cell lines and thus 
demonstrated that LMAN1 re-expression had no effect on the A1AT transcript levels 
(Fig.3.11).  
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Figure 3.10 A1AT secretion in LMAN1-proficient and LMAN1-deficient cell lines. A. 
A1AT concentration in conditioned medium was measured by an A1AT specific ELISA. 
MSI-H cell lines harboring homozygous mutations for LMAN1 (−/−) showed 3-fold lower 
levels of secreted A1AT than MSS and MSI-H cell lines with wild-type LMAN1 cMNR alleles 
(+/+). The relative A1AT concentration was adjusted to the DNA amount in 80% confluent 
cells. Lactate dehydrogenase measurement excluded distortion by dead cells. Columns: 
mean of three independent experiments; bars: standard deviation. B. Reconstitution of 
A1AT secretion upon LMAN1-cDNA transfection into a LMAN1-deficient cell line. Colo60H 
cells were transiently transfected with an LMAN1-cDNA expression vector (pcDNA3.1-
LMAN1) or empty control vector (pcDNA3.1). Forty-eight hours after transfection, there was 
a significant increase of A1AT concentration in conditioned medium compared with the 
same cell line transfected with the empty vector. 
LMAN1-deficient cell lines showed a decreased A1AT secretion and this secretion 
defect could be abolished after transient expression of LMAN1. For A1AT a 
promotion of tumor progression was reported if less A1AT was secreted [Huang et 
al., 2004]. LMAN1 mutated cells showed a decreased secretion of A1AT therefore 
suggesting a potential role of LMAN1-mediated A1AT secretion in MSI 
tumorigenesis. 
 42
  Results 
  
 
Figure 3.11 RT-PCR analysis of A1AT. RT-PCR analysis of A1AT 
expression in CRC cell lines used for A1AT ELISA. The expected A1AT PCR 
fragment of 484 bp could be amplified from cDNAs of 2 MSS cell lines 
(SW948 and Caco2), and MSI-H CRC cell lines mutated (−/−) and not 
mutated (+/+) for LMAN1, as well as transiently transfected Colo60H cells. 
As a control for cDNA, GAPDH was amplified.  
3.4.2 Protein retention in the ER/Golgi fraction changes with LMAN1 
expression 
A lack of LMAN1 transport function could affect several yet unknown glycoproteins. 
Since LMAN1 presence or absence changed the A1AT secretion it was determined 
whether LMAN1 expression or loss of expression had effects on further glycoproteins 
which are transported through the secretory pathway. First indications of the overall 
protein pattern were determined by a pulse chase experiment with LMAN1-
transfected LoVo cells (section 3.3.1). LMAN1-transfected LoVo cells and parental 
LoVo cells were pulsed with 35S-methionine medium for 30 min and chased for 30 
min. In 30 min pulse time the cells incorporated 35S-methionine into current newly 
assembled proteins. During the 30 min chase period cargo proteins are expected to 
retain in the ER/Golgi fraction in LMAN1-deficient LoVo cells compared to LMAN1 re-
expressing cells. Subsequently, proteins with incorporated 35S-methionine were 
detected and evaluated using the proteomweaver software. 164 protein spot matches 
were detected between parental LoVo cells and LMAN1-transfected LoVo cells. 
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Among these, five spots showed differences in the ER/Golgi fraction of parental LoVo 
cells compared to LMAN1-transfected LoVo cells (Fig. 3.12).  
 
 
Figure 3.12 Pulse Chase Experiment with parental LoVo cells and LMAN1-transfected 
LoVo cells. Proteins of the ER/Golgi fraction were seperated by molecular weight and 
isoelectric point using 2D-gel electrophoresis and 35S-methionine labelled protein spots were 
detected by a phosphoimager and subsequent analyzed by the Proteomweaver Sofware. The 
upper panel shows the ER/Golgi proteins that incorporated 35S-methionine within the LoVo cells 
and the lower panel represents proteins with incorporated 35S-methionine within LMAN1-
transfected LoVo cells. Spot 584 disappeared in LMAN1-transfected LoVo cells, but was visible 
in parental LoVo cells all other spots appeared in LMAN1-transfected LoVo cells and were not 
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detectable in parental LoVo cells. Overall the protein assembly rate was higher in LMAN1-
transfected LoVo cells. Detected spots are enlarged. 
One spot was present in parental LoVo cells, but absent in the LMAN1-transfected 
LoVo cells (spot 584; Fig. 3.12) whereas four spots appeared only when LMAN1 was 
re-expressed (spots 227, 428, 599 and 624; Fig 3.12). This data is in contrast to the 
expectation that cargo proteins are expected to retain in the ER/Golgi fraction. The 
apparent size and isoelectric point for each spot detected are summarized in table 
3.2. Overall, the protein expression for some proteins appeared to be higher in 
LMAN1-transfected LoVo cells compared to parental LoVo cells, with more 
incorporated 35S-methionine detectable. 
Using an initial pulse-chase experiment we obtained preliminary evidence for 
potential differences in the protein pattern in a steady-state situation between 
parental LoVo cells and LMAN1-transfected LoVo cells.  
Table 3.2 Spot analysis by the Proteomweaver Software
Spot number Apparent size in kDa 
Approximate 
isoelectric point 
LMAN1 
expression 
599 60-90 6 + 
624 40-60 6,5 + 
227 20-30 6 + 
428 50-80 8 + 
584 60-90 7 − 
Spots 599, 624, 227 and 428 appeared after LMAN1 expression, whereas spot 584 
disappeared after LMAN1 expression. Spot 624 could correspond to LMAN1 itself with a 
molecular weight of 53 kDa and a isoelectric point of 6.7 and would serve as an internal control. 
3.4.3 The LMAN1 carbohydrate recognition domain shows high 
affinity for LMAN1 substrates 
Previous published studies have analyzed LMAN1 function by using different 
constructs, including or lacking all sub-structures [Appenzeller et al., 1999; 
Appenzeller-Herzog et al., 2004; Kamiya et al., 2008]. It is currently known that 
LMAN1 binding is dependent on pH and on Ca2+ concentration. Most studies used D-
mannose to analyze LMAN1 binding properties. In this context it is important to know 
which conditions are required for binding to its specific substrates. In addition to 
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mannose it was decided to gain insight into LMAN1`s binding behavior using the 
complete cargo molecule A1AT. The aim was the purification of a functional LMAN1 
protein with the carbohydrate recognition domain (CRD) as a powerful tool in search 
of specific yet unknown LMAN1 targets.  
Two strategies were pursued to isolate functional LMAN1 protein: the 
purification of full length native protein expressed in mammalian cells and purification 
of bacterially expressed LMAN1-CRD protein followed by a refolding step. The CRD-
domain including the oligomerization-domain was cloned into the pET44a(+) vector 
for bacterial expression and full length LMAN1 cDNA was cloned into the mammalian 
expression vector pcDNA3.1 (fig. 6.1). After a successful functional binding to 
mannose sepharose the functional binding to A1AT sepharose was verified. 
Full-length LMAN1 has a weak affinity to mannose sepharose 
First, full length LMAN1 was expressed in mammalian cells to simulate almost 
identical conditions to the in vivo situation. It was considered that in mammalian cells 
correct folding conditions and important interaction partners exist. Full length LMAN1 
cDNA was cloned into the mammalian expression vector pcDNA3.1 containing the 
SV40 ori and transfected into the human embryonic kidney cell line 293T, that 
contains the SV40 large T-antigen allowing the episomal replication of the plasmid for 
high-level gene expression. The LMAN1-pcDNA3.1 construct (Fig. 6.1) did not 
contain a pre-purification tag so that protein lysate was directly purified via a 
mannose sepharose column verifying functional binding of full length LMAN1. 
LMAN1 protein only showed weak binding to mannose sepharose column and was 
washed away through all wash fractions and could not be specifically eluted by 
mannose and EGTA (Fig. 3.13). Binding to A1AT-sepharose revealed similar results 
(Data not shown). 
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Figure 3.13 Full length LMAN1 purification using mannose-sepharose. Western blot 
analysis and silver staining of protein fractions for verification of LMAN1 specificity and purity. 
The expected size of full length LMAN1 is 53 kDa. Some LMAN1 protein bound to mannose 
sepharose, but was already washed away during washing steps and could not be specifically 
eluted with mannose and EGTA. Flow Through (FT), wash (W1-W5) and elution fractions (E1-
E5). Marker bands are depicted. 
LMAN1-CRD shows specific binding to selected substrates 
LMAN1-CRD was cloned into the pET44(+)a vector and expressed in the bacterial 
strain BL21. After denaturing cell lysis, protein lysate was refolded by rapid dilution 
into 92 different buffer compositions (iFOLD System1). The binding capacity of 
refolded LMAN1-CRD protein was measured by a radioactive binding assay with 
iodinated alpha-1-antitrypsin (125I-A1AT). The radioactive binding assay is described 
in section 6.3.2. For eight out of 92 buffers analyzed the refolding conditions showed 
high affinity of LMAN1-CRD to the substrate A1AT (Tab. 3.3). Buffer condition 2 was 
chosen, containing CaCl2, which is an essential cofactor of LMAN1 for optimal 
binding to mannose-harboring glycoproteins. Large scale purification of LMAN1-CRD 
was performed under these buffer conditions using either a mannose sepharose 
column or an A1AT sepharose column. Protein purification was first performed using 
a mannose sepharose column. Highest amounts of protein were detected in flow 
through (FT) and wash fractions (W1 – W5), a slightly smaller protein was eluted in 
fraction E2, probably a partially degraded LMAN1-CRD protein. LMAN1-CRD 
showed a higher binding affinity to an A1AT sepharose column compared to the 
mannose sepharose column and was specifically eluted in fraction five (E5) with the 
expected size of 38 kDa (Fig. 3.14). The purified LMAN1-CRD showed a high binding 
capacity to A1AT sepharose column. 
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Table 3.3 Radioactive labelling using 125I-A1AT 
Buffer condition Functional binding (DPM-decay per minute) 
Control binding 
(DPM-decay per minute) 
1 15.304 1.236 
2 14.232 1.343 
3 11.005 459 
4 16.731 657 
5 15.287 1.500 
6 18.704 840 
7 17.888 1.929 
8 23.916 415 
LMAN1-CRD was analysed using 125I-A1AT and Ni2+-sepharose. LMAN1-CRD was attached to 
Ni2+ via the N-terminal histidine tag of the pET44-CRD construct and incubated with 125I-A1AT. 
Unbound 125I-A1AT was washed away, followed by elution with 1M imidazole. Eluted material 
was analysed using a liquid scintillation counter (LSC) by measuring decays per minute (DPM). In 
the control labelling experiment labelled LMAN1-CRD was directly incubated with 1M imidazole 
so that imidazole served as a competitor to refolded LMAN1-CRD preventing histidine-tagged 
LMAN1-CRD to bind on the Ni2+-sepharose. For buffer composition see table 6.1. 
The two purification strategies to receive functional LMAN1 binding showed that 
LMAN1-CRD had a higher affinity to A1AT sepharose column compared to mannose 
sepharose column and that full length LMAN1 showed no appropriate binding. Taken 
together, our results demonstrate that LMAN1-CRD was successfully and specifically 
purified using the approach described above. In addition, the A1AT sepharose 
column was established as a highly specific tool for LMAN1 purification, superior to 
mannose sepharose columns.
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Figure 3.14 LMAN1-CRD purification using mannose- and A1AT-sepharose. 
Western Blot analysis and silver staining of protein fractions for verification of 
LMAN1 protein binding and purity, the predicted size of LMAN1-CRD is 38 kDa. A. 
LMAN1 CRD did not specifically bind to mannose (FT) and was washed away (W1-
W5). A smaller band was detected in fraction E2, corresponding to degraded 
protein. B. LMAN1 CRD was able to bind to A1AT sepharose, was weakly washed 
away and specifically eluted with buffer containing mannose and EGTA (E5). Flow 
Through (FT), wash (W1-W5) and elution fractions (E1-E5). Marker bands are 
depicted.
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3.5  XYLT2 loss of function mutation in MSI-H colorectal 
tumorigenesis 
In addition to LMAN1 exhibiting transporter function, the enzyme, termed XYLT2 
(xylosyltransferase 2), was highly mutated in MSI-H CRC cell lines (35%; 8/23). 
XYLT2 catalyzes the initial step in proteoglycan synthesis (Fig. 3.15). To gain a more 
detailed insight into the role of XYLT2 in MSI-H colorectal carcinogenesis the XYLT2 
gene was further analyzed by expression profiling and functional analysis using 3H-
xylose for an incorporation assay. 
 
Figure 3.15 XYLT enzyme activity during proteoglycan synthesis [Götting et al., 2007]. 
The two XYLT enzymes catalyze the first step in proteoglycan synthesis by linking a serine 
hydroxyl group of the core protein with the first sugar xylose. 
3.5.1 Variation of XYLT2 and XYLT1 expression within MSI-H CRC 
cell lines  
Since mammalian cells can express two XYLT isoforms, expression analysis was 
performed for both gene isoforms, XYLT1 and XYLT2. Oligonucleotides spanning at 
least two exons of the gene were designed and for the XYLT2 gene the PCR product 
included the C7 cMNR. XYLT mRNA levels were investigated on 23 MSI-H CRC 
cells, one MSS cell line (SW948), normal human colon mucosa and the 
hepatocellular liver cancer cell line HepG2. For HepG2 cells a moderate XYLT2 
expression was reported [Roch et al., 2010]. XYLT2 transcript was found to be 
expressed in all tested cells, including cell lines harboring mono- or biallelic XYLT2 
cMNR frameshift mutations and was also detected in normal colon tissue and HepG2 
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cells (Fig. 3.16A). XYLT1 mRNA was also found to be expressed in all cell lines and 
normal colon tissue but not in the hepatocellular cell line HepG2 (Fig. 3.16B).  
 
Figure 3.16 XYLT1 and XYLT2 expression in CRC cell lines and control cells. A. RT-PCR 
analysis of XYLT2 expression in CRC cell lines with homozygously wild-type (+/+), 
homozygously mutant (−/−), or heterozygously mutant (+/−) XYLT2 C7 cMNR. The expected 
XYLT2 PCR fragment of 298 bp could be amplified from cDNA of normal human colon, a MSS 
cell line (SW948), and all MSI-H CRC cell lines. As a positive control for XYLT2 expression 
HepG2 cells were used. B. RT-PCR analysis of XYLT1 expression in CRC cell lines and 
HepG2 cells. The expected XYLT1 PCR fragment of 250 bp could be amplified from cDNA of 
normal human colon, a MSS cell line (SW948), and all MSI-H CRC cell lines but not from the 
hepatocellular cancer cell line HepG2.
3.5.2 XYLT2 reconstitution changes xylose incorporation in XYLT2-
deficient MSI-H CRC cell lines  
We hypothesized that XYLT2-deficient MSI-H CRC cell lines might have a lower 
xylose assembly rate compared to XYLT2-proficient cells, because XYLT2 catalyzes 
the first step in proteoglycan synthesis and links xylose to the core protein. For 
functional analysis of XYLT2 a 3H-xylose incorporation assay was chosen. In case of 
a deficiency for XYLT no xylose assembly should occur (see Fig. 3.15). Due to the 
detection of XYLT1 expression in CRC cells (Fig. 3.16B), a direct comparison of 
XYLT2-deficient and -proficient MSI-H CRC cell lines was not suitable, because 
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effects could not be attributed to XYLT2 alone. HepG2 cells only expressing XYLT2 
showed a high xylose assembly. MSI-H CRC cell lines harboring different XYLT2 
mutations, varied in their xylose assembly (Fig. 3.17) as was to be expected.  
 
Figure 3.17 Metabolic H-xylose labelling in MSI-H CRC cell lines.3  
3H-Xylose assembly was performed using CRC cell lines with 
homozygous wild-type (+/+), homozygous mutant (−/−), or heterozygous 
(+/−) cMNR status for XYLT2 and as a positive control the hepatocellular 
cell line HepG2 was used. Radioactive xylose amount was measured 
with a liquid scintillation counter in decays per minute (dpm) and protein 
amount was charged against dpm. HepG2 cells only expressing XYLT2 
showed a high xylose assembly. CRC cell lines harboring different 
XYLT2 mutations, varied in their xylose assembly. Two independent 
experiments are shown. Error bars represent standard errors. 
In addition to the effect that XYLT1 might take over the function of the XYLT2 protein, 
the genetic heterogeneity among the analyzed cancer cells account for the difference 
in xylose assembly rates. For that reason, one biallelically XYLT2-mutated MSI-H 
CRC cell line was transiently transfected with either XYLT2-cDNA or the empty 
vector control (pcDNA3.1). There was a minimal, but not significant increase, in 
xylose assembly in HDC9 cells upon XYLT2 expression (Fig. 3.18) compared to 
mock-transfected HDC9 cells, which might result from low transfection efficiency. An 
involvement of XYLT2 in xylose assembly would probably be measurable if more 
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cells express XYLT2. Results require validation in stably transfected HDC9 cells 
expressing XYLT2, which are currently established in our laboratory. 
 
Figure 3.18 Metabolic H-xylose labelling in HDC9 cells upon XYLT2 
re-expression.
3
 Cells were transiently transfected with either XYLT2 
pcDNA3.1 or the empty vector. Afterwards cells were fed with 3H-xylose 
containing medium and harvested after 48 hours. Radioactive xylose 
amount was measured with a liquid scintillation counter in decays per 
minute (dpm) and protein amount was charted against dpm. Upon 
XYLT2-transfected HDC9 cells showed a minimal increase in xylose 
assembly compared to mock-transfected HDC9 cells. Results present 
two independent experiments. Error bars represent standard errors. 
Expression analysis for XYLT2 revealed similar results to LMAN1 expression profiles. 
Biallelically XYLT2-mutated transcripts were still detectable although XYLT2-mutant 
transcript is predicted to be NMD sensitive with a PTC more than 55 base pairs 
upstream of the last exon-exon border. A changed enzyme function with regard to 
XYLT2 loss of function could not be confirmed yet. 
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4.  Discussion 
4.1 Glycogenes show high mutation frequencies in MSI-H 
CRC 
The major goals of this work were the identification and characterization of coding 
mononucleotide repeat (cMNR) harboring genes encoding proteins of the 
glycosylation machinery, and the characterization of the resulting effects on cell 
surface glycosylation. Database analysis revealed 28 cMNR-harboring genes 
encoding components of the cellular glycosylation machinery. The three glycosylation 
genes which were already brought into correlation with MSI CRC, B4GALT1, 
GALNT5 and SIAT4B [Kim et al., 2004], were not selected by this database 
preselection, because all three coding regions did not possess a cMNR of more than 
seven base pairs. Here, only new genes with an involvement in glycosylation were 
identified. 
Two genes involved in the glycosylation machinery, LMAN1 and XYLT2, 
showed mutation frequencies above the predicted frequency for the length of their 
cMNRs in MSI-H CRC cell lines, colorectal adenomas and carcinomas, suggesting a 
functional role as mutational targets in MSI tumorigenesis. In addition to the most 
frequently mutated genes, candidate genes mutated at lower frequency might 
however also be relevant for MSI tumor development.
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4.2  Genetic alterations in LMAN1 might play a role in MSI 
colorectal tumorigenesis 
4.2.1 LMAN1 transporter function in the cell 
LMAN1 (also known as ERGIC-53: ER/Golgi intermediate compartment 53 kDa) is a 
membrane protein that carries secretory proteins in COPII vesicles from the ER to 
the Golgi apparatus [Stephens et al., 2001]. LMAN1 binds as a mannose-specific 
lectin to its substrates by a luminal carbohydrate recognition domain (CRD) in the 
neutral and Ca2+-rich ER and releases its cargo in the ERGIC because of a more 
acidic environment and a lower Ca2+ concentration [Hauri et al., 2000]. LMAN1 acts 
as a transport receptor for the serine protease inhibitor A1AT [Nyfeler et al., 2008] 
and is involved in the ER-export of the lysosomal glycoproteins cathepsin C and Z as 
well as the blood coagulation factors V and VIII [Appenzeller et al., 1999; Moussalli et 
al., 1999; Nyfeler et al., 2008; Vollenweider et al., 1998]. Genetic alterations in 
LMAN1 are known to be associated with a human disease termed combined 
deficiency of coagulation factors V and VIII (F5F8D), but connections to cancer have 
not been reported so far [Spreafico et al., 2008]. 
 
Figure 4.1 LMAN1 transporter function in the cell [Hauri et al., 2000]. LMAN1 is a Type I 
mannose-binding lectin, which binds to mannose (Man9) bearing glycoproteins in the ER 
after these glycoproteins have undergone folding and quality control (3). LMAN1 monomers 
are translocated into the ER-lumen (1) and form disulfide-linked homo-hexamers (2). LMAN1 
hexamers bind to Man9-N-glycans of correctly folded cargo glycoproteins in the presence of 
Ca2+ (4). It cycles between ER and ERGIC, transporting glycoproteins to the ERGIC (5). In 
the ERGIC glycoproteins are released due to a more acidic, Ca2+-low environment (6). The 
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glycoprotein is further transported through the secretory pathway (8) and either secreted or is 
associated with the cell surface (9). The C-terminal FF-motif of LMAN1 is required as the ER 
exit signal and free LMAN1 is recruited back to the ER via direct interaction of di-lysine (KK) 
with CopI vesicles. 
Mutations of LMAN1 associated with this autosomal recessive bleeding disorder 
(F5F8D) were found throughout the whole gene sequence, including all exons 
except exon 4. Nonsense, frameshift, splicing defect or missens mutations were 
involved. In contrast, LMAN1 mutations that occurred in MSI-H tumors represent 
cMNR frameshift mutations only in exon 8 and interfere with normal LMAN1 
function probably by disrupting the control region of the oligomerization domain. 
Two conserved cysteine residues as well as four α-helices located in the 
oligomerization domain are required for the formation of homohexamers [Neve et 
al., 2005; Nufer et al., 2003]. It was reported that LMAN1 only exits the ER in a 
hexameric form suggesting that only this form is functional for transporting cargo 
proteins [Neve et al., 2005]. Frameshift mutations in the LMAN1 cMNR would 
lead to a loss of both cysteine residues and two α-helices, thus preventing 
oligomerization of LMAN1. The lack of oligomerization leads to misfolding and to 
retention in the ER by chaperones [Hurtley et al., 1989], so that a transport of 
cargo proteins would not be able anymore. This work provides the first evidence 
for LMAN1 being involved in human neoplastic disease apart from F5F8D. 
Several lines of evidence support the involvement of LMAN1 in MSI 
tumorigenesis. 
4.2.2 LMAN1 involvement in MSI-H tumorigenesis 
First, a high mutation frequency of 52% was observed in MSI-H CRC cell lines with 
biallelic mutations in 17% of the cell lines. The LMAN1 mutation frequency was 
significantly higher than the predicted frequency for the length of its cMNR of nine 
nucleotides (A9). Accordingly, LMAN1 mutations most likely are subject to positive 
selection pressure and hence might confer a growth advantage to affected MSI tumor 
cells [Woerner et al., 2010]. Second, a significant fraction of LMAN1 mutations in 
MSI-H CRC cell lines and primary tumors affected both alleles. In general, such 
biallelic mutational inactivation usually points to a tumor suppressor function of the 
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affected gene. To understand the nature of the genetic defects observed in MSI-H 
CRC cells, LMAN1 expression was analyzed at the transcript and protein level. 
Expression analysis showed that LMAN1 mRNA was expressed in all MSI-H CRC 
cell lines, including those with mono- and biallelic mutations. LMAN1-mutant 
transcripts harbor a premature termination codon, thus being predicted to be NMD-
sensitive. Messenger RNA transcripts that carry premature termination codons 
(PTCs) are recognized by the nonsense-mediated mRNA decay (NMD) system when 
the PTC appears 50 – 55 base pairs upstream of the last exon-exon border [El-Bchiri 
et al., 2005; El-Bchiri et al., 2008; Ionov et al., 2004]. NMD-sensitive transcripts 
should be recognized and degraded by the nonsense-mediated mRNA decay (NMD) 
system [You et al., 2007]. However, LMAN1 transcripts were easily detectable by RT-
PCR analysis in cell lines with biallelic frameshift mutations and hence seemed NMD 
resistant. Altered mRNA sequences that are not affected by NMD can lead to the 
generation of truncated proteins, carrying a carboxy-terminal neopeptide sequence 
due to shifts in the reading frame of the encoded amino acid sequence. These 
neopeptides appeared to be highly immunogenic [Linnebacher et al., 2001; 
Schwitalle et al., 2008], thus possibly explaining the high lymphocytic infiltration 
observed in MSI CRCs. To observe whether a truncated LMAN1 protein is expressed 
in LMAN1-mutated cell lines, Western blot analysis with an appropriate LMAN1 
antibody detecting an amino-terminal peptide was performed. Cell lines harboring 
wildtype LMAN1 or heterozygously mutated LMAN1 showed a protein band at the 
expected size of 53 kDa, but no truncated protein band of 36 kDa could be detected 
in heterozygous or homozygous LMAN1 cell lines. This suggests that mutant LMAN1 
transcript could represent a NMD-escape transcript, affected by nonsense-mediated 
translational repression [You et al., 2007] or the truncated LMAN1-mutant protein is 
recognized by ER-associated degradation (ERAD) enzymes and efficiently degraded 
by proteasomal degradation.  
Immunohistochemical analyses on a set of 50 MSI-H colorectal carcinomas 
showed local loss in 38% of all carcinomas and complete loss of LMAN1 expression 
in 6% of all carcinomas. In addition biallelic mutations, associated with complete loss 
of LMAN1 protein expression, occurred frequently in MSI-H colorectal carcinomas 
and adenomas. This was proven by regional microdissection on a few MSI-H 
carcinomas and MSI-H adenomas. DNA frameshift mutation analysis revealed 
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biallelic cMNR frameshift mutations in the LMAN1 gene and loss of LMAN1 protein 
expression in these tumor areas. Interestingly, some LMAN1-stained tumor slides 
gave the impression that LMAN1-deficient tumor regions appeared to show a higher 
invasiveness compared to areas expressing LMAN1. But due to the low number of 
tumors that showed this effect no final conclusion could be drawn. In order to 
address this issue more tumor slides should be analyzed and the metastatic behavior 
of LMAN1-deficient cell lines could be examined. Furthermore, LMAN1 mutations 
were observed through all tumor stages (UICC stages, data not shown) analyzed and 
occurred already in adenomas. Interestingly, LMAN1 mutations seemed to occur 
more frequently in hereditary MSI-H CRCs (HNPCC) than in sporadic MSI-H CRCs 
suggesting that LMAN1 mutations appear in patients with germline mutations in the 
MMR-system and are less frequent observed after epigenetic silencing of the MLH1 
promotor accompanied by BRAF mutations in sporadic MSI tumors. 
Impaired A1AT secretion in LMAN1-deficient MSI-H cancer cell lines 
The third and most striking evidence for an involvement of LMAN1 in MSI 
tumorigenesis relates to the observation that LMAN1-deficient cell lines showed 
impaired A1AT secretion. Alpha-1-antitrypsin (A1AT), a serine protease inhibitor, was 
reported to be involved in tumorigenesis [Huang et al., 2004]. Its expression is found 
in many different tissues including the human colon [Carlson et al., 1988; Geboes et 
al., 1983]. A1AT exerts anti-proteolytic function and confers angio-inhibitory activity 
[Huang et al., 2004]. Comparative cDNA microarray expression analyses of human 
normal and tumor tissues revealed that lower levels of A1AT transcripts correlated 
with larger tumor size [Huang et al., 2004] and higher levels of non-circulating A1AT 
within tumors tend to be associated with a better prognosis [Allgayer et al., 1998]. 
Interestingly, it was hypothesized that A1AT may be protective against MSI-H-CRC 
development, because increased A1AT levels in postmenopausal women receiving 
estrogen were associated with a reduced incidence for MSI-H CRC [Yang et al., 
2000]. Work by Huang and colleagues also shows significant variations in local A1AT 
levels in human tumor tissues [Huang et al., 2004]. The observation of intratumoral 
heterogeneity of local LMAN1 deficiency might provide a molecular explanation for 
this finding. The A1AT-ELISA results showed significantly lower levels of A1AT 
secreted into the cell culture medium in LMAN1-deficient cell lines, reaching about 
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20% of the level secreted by the LMAN1-proficient control cell line Caco2. These 
data on A1AT secretion correspond well with the results of Nyfeler and colleagues on 
mouse embryonic fibroblasts (MEF) derived from LMAN1 (−/−) knockout mice 
[Nyfeler et al., 2008]. LMAN1-deficient MEFs secreted only approximately 25% of 
A1AT in a given time period compared with LMAN1 (+/+) MEFs. Furthermore, the re-
expression of LMAN1 in a LMAN1-deficient cell line abolished the secretion defect, 
thus the A1AT secretion decrease could be attributed to the loss of LMAN1 
transporter function.  
A1AT has an important role in inhibiting several serine proteases with 
essential roles in processes like blood coagulation, apoptosis, cell differentiation, 
ECM degradation and inflammation. One prominent protease which is inhbited by 
A1AT is the enzyme neutrophil elastase (NE). NE is expressed in neutrophils which 
are the first immune cells arriving at a site of inflammation [Heutinck et al., 2010]. In 
addition to their function in promoting bacterial killing, NEs are involved in degrading 
ECM compounds and in migration [Korkmaz et al., 2008; Rao et al., 2004]. NE was 
reported to hydrolyze ECM compounds such as collagens, fibronectins and 
proteoglycans [Mainardi et al., 1980; McDonald et al., 1980; McGowan et al., 1989]. 
Breast tumors with high levels of free NE were associated with a poor prognosis 
[Akizuki et al., 2007]. A loss of A1AT as the inhibitor of NE could contribute to that 
effects. Proteases such as NE may play a pathological role in facilitating cancer cell 
invasion and metastasis by dissolution of the tumor matrix. Other proteases like 
proprotein convertases (PCs) were reported to play an important role in tumor cell 
metastasis in human colorectal tumor cells. Overexpression of another serine 
protease inhibitor termed α-1-antitrypsin Portland (α1-PDX) significantly reduced the 
ability of colorectal tumor cells to form liver metastasis [Scamuffa et al., 2008]. Thus 
inhibition of proteases deregulating the environment of tumor cells is an important 
task and loss of this function generates an advantage for the tumor cell. If α1-PDX 
presents also a cargo protein of LMAN1 has to be proven.  
With the A1AT secretion defects in LMAN1-deficient cell lines and the 
restoration of this defect by transient LMAN1-transfection a direct correlation 
between A1AT and LMAN1 as a specific transporter of A1AT could be made. The 
loss of LMAN1 transporter function might decrease A1AT levels in the tumor tissue 
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thus driving tumor progression or even lead the formation of metastasis by enhanced 
levels of proteases changing the ECM of the tumor [Roeckel et al., 2009]. 
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4.2.3 The screening for new LMAN1 cargo proteins 
Apart from A1AT secretion defects, alternative mechanisms could also contribute to a 
tumor-promoting effect of LMAN1 mutations. LMAN1 mutations might confer more 
indirect effects via impaired transport of known or yet unknown cargo proteins. For 
example, LMAN1 deficiency might promote MSI colorectal tumorigenesis by affecting 
the secretion of client proteins such as cathepsin C and Z or by interfering with 
interacting proteins such as MCFD2, FGFR3 and SUMF1 [Fraldi et al., 2008; Lievens 
et al., 2008; Nyfeler et al., 2006]. Moreover, it is reasonable to assume that additional 
yet unknown LMAN1 cargo proteins exist, which might be affected by a loss of 
LMAN1 function.  
To identify new LMAN1 cargo and binding proteins, two techniques were 
established: (i) a pulse-chase experiment to identify the general distribution of 
proteins in the ER of LMAN1-proficient versus LMAN1-deficient MSI-H tumor cells 
and (ii) the use of purified LMAN1 protein as a bait to capture interacting proteins. 
With the pulse chase experiment the retention of proteins upon LMAN1 re-expression 
in a LMAN1-deficient background was observed using 35S-methionine. By 
comparison of isoelectric points and molecular weights already known cargo proteins 
were excluded. With the functional purification of the LMAN1 protein an important 
tool for the identification of new LMAN1 cargo proteins was generated. An agarose-
immobilized LMAN1 protein should subsequently be used for the fishing of new 
LMAN1 cargo proteins in the medium of MSI-H colorectal cancer cells. 
Protein retention upon LMAN1 expression 
The aim of the pulse chase experiment was to identify new LMAN1 cargo proteins 
retained in the ER/Golgi fraction in LMAN1-deficient LoVo cells due to a loss of 
LMAN1 transporter function. 164 proteins with incorporated 35S-methionine were 
detected in the ER/Golgi fraction. Only five protein spots showed differences in 
LMAN1-deficient LoVo cells compared to LMAN1-transfected LoVo cells. A possible 
reason for the low number of differences detected, might be the cells`s ability to 
compensate some, but not all, of the effects caused by LMAN1 deficiency by utilizing 
other transport pathways. It is known that LMAN1 can interact with additional proteins 
representing a checkpoint for quality control of glycoproteins [Fraldi et al., 2008; 
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Lievens et al., 2008; Nyfeler et al., 2006]. The additional function of LMAN1 as a 
checkpoint together with its interaction partners could also work with other lectins, 
suggesting alternative pathways playing similar roles like LMAN1 complexes and 
taking over their function. An alternative explanation might be that retained proteins 
were detected by a certain quality control system in LMAN1-deficient cells and 
immediately degraded, because normal transport conditions were interrupted.  
However another explanation appears most likely. If one recalls that 
approximately 3000 – 4000 proteins are secreted and just as many pass the 
secretory pathway as membrane bound proteins [Bonin-Debs et al., 2004], it is 
obvious that the employed experimental strategy most likely detected only the most 
abundant proteins. Although only one potential cargo protein was detected in 
LMAN1-deficient cells, other LMAN1 cargo proteins might be present which were 
below the detection limit of this method. If LMAN1 cargo proteins remain in the 
ER/Golgi fraction but can not be detected because they are masked by high 
abundance proteins, variation and optimization of the kinetic parameters would be 
required. In particular, short pulse times in the range of minutes and extended chase 
times between two and 24 hours should be considered, thus removing the label from 
all proteins transported through the secretory pathway. Accordingly, retention of low 
abundant proteins in the ER/Golgi due to LMAN1 deficiency should be increased. To 
further reduce the sample complexity and enrich potential low abundant LMAN1 
cargo proteins, pre-fractionations could be applied before 2D-electrophoresis e.g. by 
liquid phase isoelectric focussing or chromatofocussing. Since LMAN1 is a mannose-
specific lectin, an even more specific enrichment of possible cargo proteins would be 
affinity chromatography via mannose-specific lectins.  
The pulse chase experiment in this study provides a first clue about additional 
LMAN1 cargo proteins and hence also might contribute to understand the role of 
LMAN1 in MSI tumorigenesis. For the identification of new LMAN1 cargo proteins an 
alternative labelling method with the incorporation of 13C-carbon-labelled amino acids 
could be considered. By this labelling method a mass spectrometric distinction 
between proteins with incorporated 13C and non-labelled proteins is possible. 
However, the identification of 13C-labelled proteins in stained 2D-gel spots will be 
hindered by the fact that not only the 13C-labelled proteins but all proteins including 
all ER/Golgi-resident will appear as prominent spots on the gel. In order to address 
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this issue another pre-fractionation step after ER/Golgi fractionation might be 
sufficient e.g. a subsequent fishing with the LMAN1-CRD.  
The LMAN1 carbohydrate recognition domain could provide a powerful tool for 
cargo protein detection 
An alternative experimental strategy was to apply LMAN1`s lectin function for the 
identification of new LMAN1 cargo proteins. To this end functional LMAN1 constructs 
were required.  
For functional analysis two different LMAN1 constructs were applied, the full 
length LMAN1 protein and its carbohydrate recognition (CRD)-domain. The binding 
of these constructs to two affinity matrices, mannose sepharose and A1AT 
sepharose revealed that the LMAN1-CRD construct had the highest binding capacity 
to an A1AT sepharose column. The binding of full length LMAN1 to the mannose 
sepharose column was less efficient. The results of full length LMAN1 were not in 
line with LMAN1 binding assays of Appenzeller-Herzog and colleagues [Appenzeller-
Herzog et al., 2004], although cell lysis and purification steps were performed 
identically. Appenzeller-Herzog purified the full length Myc-tagged LMAN1 via a 
mannose sepharose column and detected the LMAN1 construct indirectly by using a 
Myc-antibody. One possible explanation for the inefficient binding of full length 
LMAN1 in the experiment established in this work, might be insufficient folding upon 
synthesis in 293T cells. Unphysiologically high amounts of LMAN1 protein 
synthesized in these cells might lead to the formation of aggregates and thus 
incorrect folding of monomeric LMAN1 polypeptides. Similarly, impaired 
multimerization could contribute to inefficient binding, since for optimal LMAN1 
function hexamer formation is essential [Neve et al., 2005]. Alternatively, a co-factor 
or interaction partner of LMAN1, required for efficient binding, was missing from or 
was not expressed in 293T so that LMAN1 was not able to bind tightly to the 
mannose sepharose column.  
LMAN1-CRD was purified by a denaturing inclusion body lysis step and 
subsequent refolding was established using the iFOLD™ protein refolding system 1. 
The LMAN1-CRD construct lacked the transmembrane and cytosolic domains, so 
that bacterial expression and protein refolding as well as purification steps were 
easier to handle. In addition, it is known that only the oligomerization domain is 
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sufficient for a functional hexamerization of LMAN1 protein [Neve et al., 2005]. In 
complete, 92 buffer conditions were tested and correct LMAN1-CRD folding was 
controlled using a radioactive binding assay with 125I-A1AT. LMAN1-CRD binding to 
125I-A1AT was efficient for eight buffers. Buffer condition 2 was chosen since this 
condition showed a low dpm-value for the control and besides this buffer contained 
the cofactor Ca2+ which is essential for optimal LMAN1 binding [Zhang et al., 2009]. 
The LMAN1-CRD construct lacking the transmembrane as well as the cytosolic 
domain showed specific binding to the A1AT sepharose column, but binding to the 
mannose sepharose column was not sufficient.  
The low affinity of LMAN1 to mannose might be explained by missing 
cofactors or modifications such as phosphorylation important for LMAN1 function. It 
is known that LMAN1 can interact with additional proteins representing a checkpoint 
for quality control of glycoproteins [Fraldi et al., 2008; Lievens et al., 2008; Nyfeler et 
al., 2006]. Under certain circumstances LMAN1 needs interaction partners for the 
correct transport of cargo proteins as it was shown for the coagulation factors V and 
VIII [Nyfeler et al., 2006], where the MCFD2-LMAN1 complex forms a specific cargo 
receptor for the ER-to-Golgi transport of these proteins. Furthermore LMAN1 was 
reported to function as a checkpoint for FGFR3 maturation, allowing only functional 
receptors to reach the cell surface [Lievens et al., 2008]. There are two further 
publications where an LMAN1 checkpoint function in quality control was 
demonstrated [Anelli et al., 2007; Fraldi et al., 2008]. In both cases LMAN1 interacts 
with another protein, termed Erp44. 
Although it was reported that transmebrane and cytosolic domains are not 
sufficient for the functional binding of LMAN1, these domains might play a role in 
correct conformation of LMAN1 in addition to the efficient cofactors. 
Furthermore LMAN1 might only detect mannose in a specific conformation 
order on the cargo protein. This would explain why LMAN1 binding to A1AT 
sepharose column was more successfull. For A1AT binding best results were 
obtained at a pH of 7.4 at 4°C and Ca2+ concentrations of 1 mM. LMAN1-CRD 
protein was specifically eluted with mannose and EGTA, but also high protein 
amounts were found in the flow through fraction. 
In the present study, optimized conditions for a functional purification of 
LMAN1-CRD have been established and can now be directly applied to large scale 
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functional LMAN1 purification. Future work will concentrate on the establishment of 
experiments for the fishing of LMAN1 substrates in cell extracts and conditioned 
medium with an agarose-immobilized LMAN1-CRD.  
The LMAN1 pulse chase experiment as well as the purification of LMAN1-CRD 
revealed on one hand potential new LMAN1 cargo proteins and on the other hand an 
appropriate tool for the specific identification of new cargo proteins. Additional cargo 
proteins could explain the role of LMAN1 in MSI tumorigenesis. 
4.2.4 LMAN1 re-expression changes the cell surface glycoprotein 
pattern 
Although only secreted proteins are known as LMAN1 client proteins, one might 
speculate that membrane-bound glycoproteins may also be transported by this 
mechanism. Support for this hypothesis was gained from Lectin-FACS analysis that 
showed changes in the cell surface glycoprotein pattern occuring in LMAN1-deficient 
LoVo cells upon reconstituted LMAN1 expression. In particular, the presence of core 
substitutions and branching in N-glycans and the sialylation status of N- and O-
glycans were profiled with a lectin panel. Mock-transfected LMAN1-deficient LoVo 
cells showed a higher binding of PHA-L lectins to the cell surface compared to 
LMAN1-transfected LoVo cells, whereas jacalin (JAC) lectin binding was reduced.  
PHA-L is an N-glycosylation-specific lectin able to agglutinate lymphocytes in 
mitogenic active cells and has been termed the “L” subunit, for leuco-agglutinin 
instead of the PHA-E lectin agglutinating erythrocytes [Leavitt et al., 1977]. As 
mentioned in section 2.5.1, PHA-L is as a marker for N-glycans bearing the β1-6 
branch. The synthesis of the β1-6 branch is catalyzed by the enzyme GlcNAcT-V 
(MGAT5), which was shown to be hyperactive in the progression of cancer from a 
tumorigenic to a metastatic phenotype [Demetriou et al., 1995; Dennis et al., 1999; 
Przybylo et al., 2008]. LMAN1 loss might influence tumor progression, but how 
LMAN1 loss can contribute to a higher β1-6 branching is difficult to reconcile. The 
disturbance of the branching relation on the cell surface might in general influence 
the balance. Increased β1-6 branching could lead to a decrease of other branches for 
cell-cell communication and thus influene cell behavior. Perhaps LMAN1 loss leads 
to an uncontrolled transport of overexpressed MGAT5 resulting in upregulated β1-6 
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branching on the cell surface. Seelentag and colleauges observed an increase in β1-
6 branches in metastatic colon carcinoma cells [Seelentag et al., 1998]. For LMAN1-
deficient MSI-H CRC cells a test for metastatic behavior, as well as the 
overexpression of MGAT5 should be performed to understand the correlation of 
LMAN1 deficiency and increased β1-6 branching. In addition, it is well documented 
that effects of β1-6 branches in glycoproteins may trigger cell growth, motility, cell 
adhesion and differentiation [Mendelsohn et al., 2007]. These N-glycan branches 
generate ligands for lattice-forming lectins, like galectins, that regulate surface levels 
of glycoproteins including epidermal growth factor (EGF) and transforming growth 
factor-beta (TGFß) receptors [Lau et al., 2007]. Influences on signalling in LMAN1-
deficient cells were not addressed yet, but warrant further investigation. 
JAC is an O-glycoside-specific lectin binding to oligosaccharide structures 
containing GalNAc, also called Tn-antigens. JAC will also bind to these structures in 
a mono- or di-sialylated form thus allowing an earlier recognition of changed O-
glycan structures. Surprisingly, PNA another lectin detecting higher sialylated Tn-
antigens failed to show a differential staining pattern to the cell surface upon LMAN1 
re-expression. The Tn-antigen was reported to be present on most human cancers 
[Springer, 1984]. Mock-transfected LoVo cells bound less JAC lectins compared to 
LMAN1-transfected LoVo cells, thus LMAN1-deficient cells did not possess a great 
portion of Tn-antigens on the cell surface. As described in section 2.5.2 Tn-antigens 
are incompletely glycosylated mucins containing less total carbohydrate, and 
frequent sialylated core 1 structures. Possibly enzymes necessary for the elongation 
of O-glycans were no longer transported by LMAN1, thus leaving the O-glycan 
incompletely glycosylated. Conversely, glycoproteins transported by LMAN1 can be 
O-glycosylated in the Golgi apparatus in addition to their N-glycosylation on serine or 
threonine residues of the same protein, so that the higher binding of JAC to the cell 
surface of LMAN1-transfected cells could be explained.  
PSA and WGA showed also less binding to glycan structures on the cell 
surface of LMAN1-deficient LoVo cells compared to mock-transfected LoVo cells. 
PSA has specificity towards α-linked mannose-containing oligosaccharides with core 
fucose and WGA shows specificity towards N-acetylglucosamine structures 
[Monsigny et al., 1980; Tateno et al., 2009]. Core fucosylation of N-glycans is a 
common modification on membrane proteins in humans. Fucosylated N-glycans 
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exhibit a smaller degree of conformational flexibility and lower flexibility increases the 
lifespan of some serum proteins. Fucosylated N-glycans are involved in a variety of 
biological and pathological processes [Ma et al., 2006].  
Overall, loss of LMAN1 expression led to a cell surface glycoprotein pattern 
different from the pattern observed on LoVo cells re-expressing LMAN1. More PHA-L 
lectins bound on the cell surface suggested more β1-6 branching in LMAN1-deficient 
cells, a glycosylation pattern known to be involved in the progression of cancer from 
a tumorigenic to a metastatic phenotype [Demetriou et al., 1995; Dennis et al., 1999; 
Przybylo et al., 2008]. LMAN1-deficient MSI-H CRC cells will be tested for an 
involvement in metastatic behavior in future experiments. 
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4.3  Consequences of XYLT2 mutations in MSI-H colorectal 
tumors 
XYLT2 catalyzes the transfer of xylose from UDP-xylose to selected serine residues 
of a core protein representing the initial enzyme in proteoglycan biosynthesis (Fig. 
4.2). Proteoglycans are present in the extracellular matrix and on the cell surface, 
playing a key role in cellular signalling, as storage depots for growth factors and 
cytokines, and interaction with a broad variety of counterpart molecules [Iozzo, 1998]. 
Two xylosyltranferase isoforms (XYLT1 and XYLT2) are found that are differentially 
expressed in cell types and tissues [Götting et al., 2007] They serve as biochemical 
markers in systemic sclerosis [Götting et al., 1999] and are associated with several 
other diseases like Pseudoxanthoma elasticum, diabetic nephropathy and 
osteoarthritis [Götting et al., 2007]. Changed expression in glycosyltransferases like 
XYLT2 will probably change the glycosylation pattern on the cell surface. Cell surface 
changes will possibly affect cell-cell interaction or cell-matrix interactions. In general, 
the glycan profile of tumor cells shows quantitative differences with increased and 
decreased expression compared to normal cells [Gabius H-J, 2009]. Mucin-type O-
glycans, Lewis antigens and Tn-antigens are already used as tumor markers for 
different tumor entities, like colorectal cancer, breast cancer, pancreatic and prostate 
cancer [Brockhausen, 2006]. This study reported for the first time XYLT2 mutations in 
MSI-H colorectal tumors. The XYLT2 C7 cMNR showed the second highest mutation 
frequencies with 35% on MSI-H CRC cell lines, 26% on MSI-H colorectal carcinomas 
and 21% on MSI-H colorectal adenomas. Furthermore, biallelic XYLT2 mutations 
were observed in two cell lines and XYLT2 was predicted as a positive selected 
gene, thus suggesting XYLT2 as a tumor-promoting gene with a presumably tumor 
suppressor function. Expression analysis of both XYLT genes showed that XYLT1 
transcript was detected in all MSI-H CRC cell lines, as well as the control cell lines 
SW948 and normal colon mucosa but not in the XYLT2 positive control cell line 
HepG2. XYLT1 presents the second isoform of XYLT genes in mammals, but without 
a cMNR in its coding region. XYLT2 mRNA was transcribed in all MSI-H CRC cell 
lines, including HDC9 and Colo60H cells, that are biallelically mutated for XYLT2. 
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Figure 4.2 XYLT metabolism in mammals (modified from [Bakker et al., 2009]). XYLT 
enzymes 1 and 2 catalyze in a tissue specific manner the intial reation in glycosaminoglycan 
(GAG) biosynthesis. UDP xylose is synthesized in two steps by the enzymes UGDH (UDP-
Glycose dehydrogenase), forming UDP-GlcA, and UXS (UDP-Xylose synthase). One 
transporter is capable of transporting UDP-GlcA over the ER-membrane, whereas the other 
transports UDP-xylose over the Golgi membrane. After the tetrasaccharide linker either 
GalNAc-GlcA or GlcNAc-GlcA disaccharide units are attached to form chondroitin and 
dermatan sulfate or heparin and heparan sulfate. 
Mutated XYLT2 transcript should be a subject of nonsense-mediated mRNA decay 
(NMD; [You et al., 2007]. The interesting question was whether a truncated XYLT2 
protein is expressed in biallelically mutated cells or if the transcript is subjected to 
nonsense-mediated translational repression [You et al., 2007] or the truncated 
protein is degraded in the proteasome. So far no appropriate antibody specifically 
detecting the XYLT2 protein is available.  
 3H-xylose incorporation experiments have demonstrated no differences in 
MSI-H CRC cell lines and in comparison a high 3H-xylose incorporation rate in control 
cells HepG2. For HepG2 cells, only expressing the XYLT2 isoform, 3H-xylose 
incorporation could be attributed to XYLT2 enzyme activity alone. XYLT1 expression 
taking over the function of XYLT2, as well as the heterogeneity of examined cancer 
cell lines might contribute to the contradictory effects in different XYLT2 mutated 
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MSI-H CRC cell lines. To investigate solely XYLT2 function 3H-xylose incorporation 
could be examined in cell lines deficient for both isoforms or XYLT1 expression could 
be silenced by XYLT1 siRNA. For the mutant chinese ovary hamster cell line CHO 
pgsA-745 no XYLT1 and XYLT2 transcripts were detected which was accompanied 
by lost chondroitin and heparan sulfate structures on the cell surface [Cuellar et al., 
2007; Esko et al., 1985]. For further analysis in MSI-H colorectal cancer cell lines a 
XYLT2-deficient cell line (HDC9) was used for overexpressing XYLT2. Changed 3H-
xylose incorporation in these cells could be directly linked to higher levels of XYLT2 
expression. To prove that decreased or increased XYLT2 expression influences the 
3H-xylose incorporation rate, HDC9 cells were transiently transfected with either the 
empty vector control pcDNA3.1 (mock-transfected HDC9 cells) or XYLT2-cDNA 
(XYLT2-transfected HDC9 cells). The effects of 3H-xylose incorporation in mock-
transfected HDC9 cells and XYLT2-transfected HDC9 cells showed only a slight 
increase in 3H-xylose in HDC9 cells re-expressing XYLT2. These low effects in 3H-
xylose incorporation were probably caused by low transfection efficiency which was 
less than 10% for HDC9 cells. The effects of XYLT2 in 3H-xylose incorporation, could 
be more reliably evaluated if more cells expressed XYLT2. This could be 
accomplished in stably transfected HDC9 cells expressing XYLT2, which are 
currently established in our laboratory. In addition to a total 3H-xylose metabolic 
labelling the incorporation rate into individual mucin proteins should be analyzed in 
future experiments. 
Taken together, the results for XYLT2 on MSI-H CRC cell lines and tumors 
showed that XYLT2 is mutated frequently and biallelically and mutations occur in 
preneoplatic lesion thus providing first evidence for an involvement in MSI 
tumorigenesis. To further validate these results additional data on XYLT2 protein 
expression need to be acquired in MSI-H CRC cell lines and primary tissues. 
Unfortunately, suitable XYLT2-specific antibodies are not available. Alternatively, 
XYLT2 enzyme activity or loss of activity could be examined in MSI-H colorectal 
tumor tissues known to carry biallelic mutations. 
How might XYLT2 loss of function contribute to MSI-H tumorigenesis? In 
contrast to almost all other glycosyltransferases the xylosyltransferases are secreted 
into the extracellular space, although xylosylation of the core protein occurs in the 
Golgi apparatus [Götting et al., 1999; Götting et al., 2000]. It was shown that 
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xylosyltransferases are secreted into the extracellular space together with large 
chondroitin sulfate proteoglycans [Götting et al., 2002], probably controlling 
proteoglycan synthesis. If the mutated XYLT2 protein is also secreted, this XYLT2 
neopeptide would be a suitable marker for MSI tumorigenesis. Functional evidence 
for XYLT contributing to tumorigenesis and especially of XYLT2 to MSI tumorigenesis 
was not determined yet. However, as an initial enzyme in proteoglycan synthesis 
XYLT2 loss probably changes cell surface structures due to a loss of chondroitin, 
dermatan and heparan sulfates. Significant changes in proteoglycan content have 
been reported in the stroma surrounding tumors, and it has been suggested that 
these alterations can support tumor growth as well as progression and invasion 
[Iozzo et al., 1993; Lesley et al., 1997]. The proteoglycan content in XYLT2-deficient 
cells and tumors has to be proven. 
The current data for the first time provide a preliminary evidence for potential 
association of XYLT2 mutations with MSI tumorigenesis. Finding evidence for 
changed XYLT2 activity in MSI-H colorectal tumors would be of great interest, since 
XYLT2 could be a promising marker for MSI-H tumorigenesis, as measuring the 
XYLT2 activity in patient`s bloods or other body fluids is efficient. 
4.4  Candidate genes with lower mutation frequency or no 
mutations in their cMNRs 
In addition to LMAN1 and XYLT2, cMNR-harboring glycosylation genes with lower or 
no mutation frequency were observed in DNA frameshift mutation analysis. These 
genes will be shortly discussed here.  
B4GALNT4 (beta-1,4-N-acetyl-galactosaminyl-transferase 4), the second gene 
mutated in more than 30% of MSI-H CRC cell lines, might be an interesting 
candidate for further analysis. B4GALNT4 harbors three cMNRS (3 x G7) in its 
coding region, so mutations may result in three different neopeptides, if mutated 
proteins are expressed. However, no biallelic mutations were observed for 
B4GALNT4 making a role as a classical tumor suppressor less likely for this gene. As 
a galactosaminyl-transferase B4GALNT4 catalyzes the linkage of N,N-diacetyl-
lactose-diamine (LacdiNAc) which is found on glycoproteins and glycohormones of 
several tissues [Gotoh et al., 2004]. It was reported that B4GALNT4 showed an 
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elevated expression in prostate cancer, together with fucosyltransferase I (FUT1) 
which is responsible for the high amount of PSA (prostate-specific antigen) in 
prostate cancer [Fukushima et al., 2010]. Expression analyses of B4GALNT4 in MSI-
H CRC have yet not been investigated. 
Furthermore glycogenes not mutated in any MSI-H CRC cell line might play 
such an important role that mutations are suppressed in these genes. Genes as ABO 
(alpha 1-3-N-acetylgalactosaminyltransferase), GOLGA4 (Golgin A 4) or OSGEPL1 
(O-sialoglycoprotein endopeptidase-like 1) might have important functions so that 
mutations in these genes are not compatible with cell survival and/or proliferation. 
ABO encodes proteins determining the individual blood groups dependent on the 
expressed splice variant, with three main variant alleles A, B and 0 [Novaretti et al., 
2008]. AB0 is known to be involved in pancreatic carcinogenesis and frequently 
shows alterations in tumors, known as Lewis antigens [Brockhausen, 1999; Wolpin et 
al., 2010]. AB0 blood type could be incorporated into predictive models for pancreatic 
cancer, because there was a tendency that blood types A, AB, and B were at greater 
risk for developing pancreatic cancer [Wolpin et al., 2010]. For GOLGA4 a potential 
role in dendrocyte differentiation and/or maturation was reported [Cowan et al., 
2002]. For OSGEPL1 only expression analyses made by the human protein atlas 
consortium (www.proteinatlas.org) are available showing a strong staining in a few 
CRCs. 
 This thesis investigated cMNR harboring genes with high mutation frequencies 
in MSI-H colorectal cancer. The analysis of genes showing no mutation frequency 
might also be interesting to understand the biology of MSI tumors.  
4.5  Conclusions and Perspectives 
During the course of this thesis a few frequently mutated genes involved in 
glycoprotein synthesis and modification were identified in MSI CRC. Two candidates 
with significantly increased mutation rates were identified (LMAN1, XYLT2). For 
these genes insights into potential mechanisms for tumor progression were 
evaluated, namely biallelic mutations in both genes led to changed glycosylation 
patterns on the cell surface. The examined cell surface glycoprotein pattern in 
LMAN1-deficient cells revealed structures known to be involved in the progression of 
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cancer from a tumorigenic to a metastatic phenotype. LMAN1 and XYLT2 mutations 
occurred frequently, early and biallelically in MSI-H CRC tumors. Expression analysis 
identified LMAN1- and XYLT2-deficient cell lines providing valuable tools for studying 
the functional consequences of protein inactivation. The results in primary MSI-H 
tumor tissues frequently show heterogeneous LMAN1 expression abnormalities 
caused by regional biallelic cMNR frameshift mutations in tumor cells. LMAN1 
mutations led to decreased secretion of a known tumor growth affecting serine 
protease inhibitor, A1AT. The loss of LMAN1 transporter function might also 
decrease A1AT levels in tumor tissues and thus drive tumor progression. Hence, it 
would be interesting to verify this assumption by determining the A1AT 
immunohistochemical staining pattern in LMAN1 negative areas. The use of a pulse 
chase experiment showed that the method in general provides a good platform for 
the identification of new LMAN1 cargo proteins but several optimization steps have to 
be performed to detect the probably low abundant proteins. Optimized conditions for 
a functional purification of LMAN1-CRD could be established during this thesis, 
however the amounts of protein have to be scaled up. An agarose-immobilized 
LMAN1-CRD domain allows direct fishing of new LMAN1 cargo proteins. Additional 
cargo proteins with an involvement in tumorigenesis like A1AT would support, 
strengthen and/or even explain the role of LMAN1 in influencing MSI tumor 
progression. 
By analyzing the transporter gene LMAN1 and the xylosyltransferase gene 
XYLT2 this thesis identified two members of the cellular glycosylation machinery as 
novel MSI target genes. At least for the LMAN1 gene loss of function leads to severe 
consequences i.e. secretion defects and an altered cell surface glycosylation pattern. 
How these alterations might affect cell-communication, signalling mechanisms and in 
general the biology of MSI tumors and warrants further investigation.  
Moreover, altered glycosylation pattern are expected to result in altered 
glycopeptides that could provide an additional source of MSI tumor-specific antigenic 
peptides complementary to the well-known frameshift neopeptides potentially useful 
for therapeutic application (vaccination).  
Finally, uncovering novel LMAN1-interacting proteins might enhance the 
understanding of the specificity of the secretory pathway, and in addition, give a more 
detailed insight into the molecular pathogenesis of MSI tumors. 
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5.  Materials 
5.1  Instruments 
Instrument (Specification) Supplier 
Agarosegel Chamber Sub Cell GT  Biorad (München, Germany) 
ÄktaPurifier FPLC System GE Healthcare (München, Germany) 
Analytical scale (BP 210 D) Sartorius (Göttingen, Germany) 
Camera (Electrophoresis Docu System 120) Kodak (Stuttgart, Germany) 
Centrifuge (5810R) Eppendorf (Hamburg, Germany) 
Centrifuge (Biofuge 13) Heraeus Holding GmbH (Hanau, Germany) 
Centrifuge (Microcentrifuge 1-14) Sigma Laborzentrifugen (Osterode, Germany) 
Centrifuge (Sigma 3MK) Sigma Laborzentrifugen (Osterode, Germany) 
Centrifuge (Varifuge 3.0R) Heraeus Holding GmbH (Hanau, Germany) 
Centrifuge Heraeus (Modell T 110 L) Heraeus Holding GmbH (Hanau, Germany) 
Digital pH Meter pH 525 WTW (Weilheim, Germany) 
Electrophoresis chamber (Sub Cell GT) Biorad (München, Germany) 
Electroporator for cells (Nucleofector 1)  Lonza Biosystems (Basel, Switzerland) 
ELISA-Reader (GENios) GENios Tecan (Crailsheim, Germany) 
FACS (FACSCalibur) Becton Dickinson (Franklin Lakes, USA) 
Genetic analyzer (ABI 3100) Applied Biosystems (Darmstadt, Germany) 
Incubator (BD6220) Fisher Scientific (Loughborough, UK) 
Liquid Scintillation Counter (TRI-CARB 2900) Perkin Elmer (Boston, USA) 
Microscope (DMBRE) Leica (Bensheim, Germany) 
Microscope (Leica DMIL) Leica (Bensheim, Germany) 
Microscope CK 40 Olympus Europa Holding GmbH (Hamburg) 
NuPAGE MES Running buffer Invitrogen (Karlsruhe, Germany) 
NuPAGE X-Cell Sure Lock  Invitrogen (Karlsruhe, Germany) 
NuPAGE ZOOM IPG Runner Cassette Invitrogen (Karlsruhe, Germany) 
NuPAGE Protein Electrophoresis System Invitrogen (Karlsruhe, Germany) 
PCR system (GeneAmp 22400) Perkin Elmer (Waltham, USA) 
PH meter (Calimatic 761) Knick (Berlin, Germany) 
Phosphorimager (FLA-3000) Fujifilm (Düsseldorf, Germany) 
Photometer (Ultrospec 3300) Amersham Pharmacia (Cambridge, UK) 
Pipet aid (Pipetman) Gilson (Limburg-Offheim) 
Pipettes (2 µl; 10 µl; 20 µl; 200 µl; 1000µl) Gilson (Limburg-Offheim) 
Power supply (Consort E835) Peqlab (Erlangen, Germany) 
Power supply (Power Pac 300) Biorad (Munchen) 
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Robo Cycler Gradient96 Stratagene (Boeblingen, Germany) 
Shaker (Certomat H) Sartorius (Göttingen, Germany) 
Sonopuls Homogenizer (Bandelin-Sonopuls) Bandelin electronic GmbH (Berlin, Germany) 
Thermomixer (5436) Eppendorf (Hamburg, Germany) 
Ultracentrifuge (TLA-100.2 rotor) Beckmann Coulter (Krefeld, Germany) 
Ultra-Low Temperatur Freezer MDF-U53V Sanyo (München, Germany) 
UV Transilluminator Konrad Benda Laborgeräte (Wiesloch, Germany) 
Vortex (MS1 Minishaker) IKA (Staufen, Germany) 
Waterbath (Grant SUB6) Grant (Cambridge, UK) 
Waterbath (SW 20) Julabo Labortechnik (Seelbach, Germany) 
5.2 Consumables, reagents and chemicals 
Item Supplier 
125I-iodine (100 mCi/ml) Hartmann Analytic (Braunschweig, Germany) 
35S-methionine (10 mCi/ml) Hartmann Analytic (Braunschweig, Germany) 
37% formaldehyde Carl Roth (Karsruhe, Germany) 
[1-3 3H]-D--xylose (10 mCi/ml) Hartmann Analytic (Braunschweig, Germany) 
Acetic acid Serva (Heidelberg, Germany) 
Alpha1-Antitrypsin Biopur (Bubendorf, Germany) 
Alpha1-Antitrypsin-Agarose Biopur (Bubendorf, Germany) 
Ampicillin sodium salt Sigma-Aldrich (Taufkirchen, Germany) 
Bacto-Agar Fluka Chemie GmbH (Buchs, Switzerland) 
beta-cyclodextrin Promega (Madison, USA) 
BigDyeTerminator v1.1 Sequencing Kit Applied Biosystems (Darmstadt, Germany) 
Boric acid Merck (Darmstadt, Germany) 
Bovine Serum Albumin (BSA) Sigma-Aldrich (Taufkirchen, Germany) 
CaCl2 Merck (Darmstadt, Germany)  
Citric acid Merck (Darmstadt, Germany) 
Diaminobenzidine (Liquid DAB+ substrate) DAKO (Hamburg, Germany) 
Dimethyl sulfoxide (DMSO) Merck (Darmstadt, Germany) 
Disodium hydrogen phosphate (Na2HPO4) VWR International GmbH (Bruchsal, Germany)  
DMEM / Ham's F-12 with L-Glutamine PAA (Cölbe, Germany) 
dNTP-Mix Invitrogen (Karlsruhe, Germany) 
Dulbecco's PBS (1x) without Ca & Mg PAA (Cölbe, Germany) 
Ethanole absolute Merck (Darmstadt, Germany) 
Ethidiumbromide Sigma-Aldrich (Taufkirchen, Germany) 
Ethylene glycol tetraacetic acid (EGTA) Sigma-Aldrich (Taufkirchen, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Merck (Darmstadt, Germany) 
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Fetal Calf Serum (FCS) Invitrogen (Karlsruhe, Germany) 
Folin-Ciocalteu phenol reagent Merck (Darmstadt, Germany) 
FuGENE HD Transfection Reagent Roche (Mannheim, Germany) 
G-418 Sulphate PAA (Cölbe, Germany) 
Gel-Dry Drying Solution Invitrogen (Karlsruhe, Germany) 
Glycerol 86% Carl Roth GmbH (Karlsruhe, Germany) 
Guanidine-hydrochloride Novagen/Merck (Darmstadt, Germany) 
HEPES Invitrogen (Karlsruhe, Germany) 
HIDI-formamide Applied Biosystems (Darmstadt, Germany) 
Horse serum Vector Laboratories (Burligame, USA) 
Isopropyl ß-D-1-thiogalactopyranoside (IPTG) Sigma-Aldrich (Taufkirchen, Germany) 
Kodak BioMax films Sigma-Aldrich (Taufkirchen, Germany) 
L-Arginin-hydrochloride Novagen/Merck (Darmstadt, Germany) 
Lipofectamine 2000 Reagent Invitrogen (Karlsruhe, Germany) 
Mannose sepharose 4B GALAB (Geessthacht, Germany) 
Methanol Merck (Darmstadt, Germany) 
MgCl2 Merck (Darmstadt, Germany)  
Milk powder Carl Roth GmbH (Karlsruhe, Germany)  
NaOH AppliChem (Darmstadt, Germany) 
Ni2+-sepharose (HisTrap FF) GE Healthcare (Uppsala, Sweden) 
N-Laurosylsarcosine  Merck (Darmstadt, Germany) 
NuPAGE 4 – 12% Bis-Tris Mini Gel  Invitrogen (Karlsruhe, Germany) 
Oligo(dT) primers  Invitrogen (Karlsruhe, Germany) 
PEG-6000 Sigma-Aldrich (Taufkirchen, Germany)  
Penicillin / Streptomycin (100x) PAA (Cölbe, Germany) 
Pierce Iodination Beads Thermo Scientific (Rockford, USA) 
Potassium chloride J.T. Baker (Deventer, Holland) 
Potassium dihydrogenphosphate Gerbu Biochemicals (Gaisberg, Germany) 
Potassium sodium tartrate (KNaC4H4O6 ) Merck (Darmstadt, Germany) 
RPMI 1640 with L-glutamine PAA (Cölbe, Germany) 
RPMI-1640 without methionine and L-glutamine Sigma-Aldrich (Taufkirchen, Germany) 
Silver nitrate (AgNO3 ) Carl Roth GmbH (Karlsruhe, Germany)  
SOC-medium Invitrogen (Karlsruhe, Germany) 
Sodium acetate (C2H3NaO2) J.T. Baker (Deventer, Holland) 
Sodium bisulfite (Na2S2O3) Merck (Darmstadt, Germany)  
Sodium carbonate (Na2CO3) J.T. Baker (Deventer, Holland) 
Sodium Chloride (NaCl) AppliChem (Darmstadt, Germany) 
Trichloracetic acid (TCA) Carl Roth GmbH (Karlsruhe, Germany)   
Tris (2-carboxyethyl) Phosphine HCl (TCEP) Novagen/Merck (Darmstadt, Germany) 
Tris Base Carl Roth GmbH (Karlsruhe, Germany) 
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Triton-X-100 Sigma-Aldrich (Taufkirchen, Germany) 
Trypsin-EDTA (1x) 0,05 % / 0,02 % in D-PBS PAA (Cölbe, Germany) 
Trypton/Pepton aus Casein Carl Roth GmbH (Karlsruhe, Germany) 
Tween-20 Sigma-Aldrich (Taufkirchen, Germany) 
Ultima Gold LSC Cocktail  Perkin Elmer (Boston, USA) 
UltraPureTM Agarose Invitrogen (Karlsruhe, Germany) 
Western Lightning Chemiluminescence 
Reagent Plus Perkin Elmer (Boston, USA) 
Yeast extract  Carl Roth GmbH (Karlsruhe, Germany) 
5.3  Commercially available kits 
Item Supplier 
A1AT-ELISA ImmunDiagnostik (Bensheim Germany) 
Biorad Protein Assay  BioRad (München, Germany) 
CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) Promega (Mannheim, Germany) 
DNeasy Blood & Tissue Handbook Qiagen (Hilden, Germany) 
Endo-free Plasmid Maxi Kit Qiagen (Hilden, Germany) 
Endoplasmic Reticulum Isolation Kit Sigma-Aldrich (Taufkirchen, Germany) 
High Pure PCR Product Purification Kit Roche (Mannheim, Germany) 
iFold Protein Refolding System 1 Novagen/Merck (Darmstadt, Germany) 
JetQuick Gel Extraction Kit Genomed (Löhne, Germany) 
NucleoSpin Plasmid Kit Machery Nagel (Düren, Germany) 
QIAfilter Plasmid Purification Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit  Qiagen (Hilden, Germany) 
RNeasy blood and tissue kit Qiagen (Hilden, Germany) 
Vectastain Elite ABC kit Vector (Burligame, USA) 
5.4 Enzymes, bacteria, antibodies, markers and vectors 
Item Supplier 
Enzymes
Calf Intestinal Phosphatase (CIP) Roche (Mannheim, Germany) 
T4-Ligase Roche (Mannheim, Germany) 
Taq-Polymerase Invitrogen (Karlsruhe, Germany) 
Phusion High Fidelity Taq-Polymerase New Englan Biolabs (Frankfurt, Germany) 
SuperscriptII Reverse Transcriptase Invitrogen (Karlsruhe, Germany) 
KpnI Promega (Madison, USA) 
NotI Promega (Madison, USA) 
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Enterokinase  Novagen/Merck (Darmstadt, Germany) 
  
Bacteria 
DH5 alpha Invitrogen (Karlsruhe, Germany) 
BL21 (DE3) Invitrogen (Karlsruhe, Germany) 
  
Antibodies (clone, dilution, specification)
LMAN1 (polyclonal, 1:1000, none) Sigma-Aldrich (Taufkirchen, Germany) 
Actin (monoclonal C4, 1:10.000, none) MP Biomedicals (Solon, USA) 
Anti-rabbit IgG (1:2500, HRP Conjugate) Promega (Madison, USA) 
Anti-mouse IgG (1:5000, HRP conjugate)  GE Healthcare (Munich, Germany) 
Anti-mouse/anti-rabbit antibody (1:50,biotinylated) Vector (Burligame, USA) 
  
Streptavidin-conjugated fluorescence
Streptavidin ⁄ R-phycoerythrin  Sigma-Aldrich (Taufkirchen, Germany) 
    
protein molecular weight markers   
See blue plus pre-stained protein standard Invitrogen (Karlsruhe, Germany) 
Mark12 unstained standard Invitrogen (Karlsruhe, Germany) 
    
DNA markers   
1 kb DNA ladder Invitrogen (Karlsruhe, Germany) 
100 bp DNA ladder Invitrogen (Karlsruhe, Germany) 
ROX size standard Applied Biosystems (Darmstadt, Germany) 
    
Vectors   
pET44a(+) Novagen/Merck (Darmstadt, Germany) 
pcDNA3.1 Invitrogen (Karlsruhe, Germany) 
5.5 Oligonucleotides 
Table 5.5.1 Oligoneucleotides designed for Frameshift mutation analysis 
Gene name (Ensembl) Sequence (5`- 3`) 
Abo_a GGACGAGGGCGATTTCTACT 
Abo_sf TCAGGTGGCTCTCGTCGT 
Alg12_c7a_a TCTTGGGGCACCTAAGACAG 
Alg12_c7a_sf TGGGATGCCTGTGAATACAA 
Alg12_c7b_a TCCCATTTCAACTACCCAGG 
Alg12_c7b_sf GTCGGAGCCACAGCAGTC 
B3galtl_a TACATAACTGGCAGACCCCC 
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B3galtl_sf GGAATTGTATTCGTCATCCAGAG 
B4galnt1_a TGTGTAGCTGGGCTCTGATG 
B4galnt1_sf AGCTCGGACTTGTTTCTGGA 
B4galnt4_g7a_a GTGAAGTTCAGTGGCAGCCT 
B4galnt4_g7a_sf GTGTGTGTGACCTCCTCCCT 
B4galnt4_g7b_a CCCCCTCTCACTGAGGAAA 
B4galnt4_g7b_sf GTCAGCCTTGAAGATGGACC 
B4galnt4_g7c_a ATAAATCCCCCTTCCCCATT 
B4galnt4_g7c_sf GAGGAGTTCCGAGACCAGTG 
B4galt2_a CAGAGAAGGAGCACAGCCTT 
B4galt2_sf CCTGACCTGCTGGATCTGTT 
Casd1_a GCAACTACAAAGAAATTTCACACG 
Casd1_sf TCCCCTTGGTCACTGTATGG 
Chgut_a AGTCAGCGTTGTAGAAGCAGC 
Chgut_sf CCCTGTCACCACAGAGATCA 
Chsy1_a CTCTTTCTTGGGCAGACAGG 
Chsy1_sf ACCATTCTCCGAAGCACCT 
Dpagt1_a GACCAAGGTTTGCAGAGGAA 
Dpagt1_sf AGAGCAATCCCAAAGTGGTG 
Galntl1_a CCTTAGAGCAGGTCCTCACG 
Galntl1_sf GGGAAAGTATGATGCCCAGA 
Gcnt2_a CCACATAGGCAGAGCCAAAG 
Gcnt2_sf TCATGCAATTGGACGGACTA 
Gcnt4_a TGAACTTAGACGGGTGCCTT 
Gcnt4_sf CAAAATAAGCACTGCCAACAAA 
Gcs1_a TGTCTTCTGGACCTCCAACC 
Gcs1_sf CTCTGTCCTCCCACTTCAGG 
Glt8d1_a CTTTGTCCCAAATGCTCTCC 
Glt8d1_sf AGCGAGTGTTGTGCTGAATG 
Golg4_a TTTTTCGGATAGGCTGATGC 
Golga4_sf TGTCACATTGATGAAAGAAGAGC 
Gyltl1b_a CACAAGGGTGACATCGTGAG 
Gyltl1b_sf AGACCCCTGCTTTGAGTTCC 
Lman1_a GGAGGAATTTGAGCACTTTCA 
Lman1_sf CACCCATGTCAGCTTTGCTA 
Man1b1_a AACTGCTTGAATGCGAGTCC 
Man1b1_sf CAACCTGTTTGAGAGCACGA 
Osgepl1_a GCTAATCTTGACTAAGACTGCAGGA 
Osgepl1_sf TGAAGAAATAGTGTTCCAGGATGA 
Pigb_a AAAATCATTTGCCTCTGTTCTAAAG 
Pigb_sf GAGTTTGTCTCTGATGATTGATCG 
Pigz_c7_a AGCACACCCACCCACTACAC 
Pigz_c7_sf ATGTCCACCACCTCCACTG 
Pigz_g7_a CAGTGGAGGTGGTGGACAT 
Pigz_g7_sf CAGGGGTTACCACAAAGAGG 
St6galnac6_a GTCTCATTCGTGGTTGAGCA 
St6galnac6_sf GAGGGCTCACCTGCAGTAGT 
St8sia6_a TTTTTAATTTGGCAGATATGGGA 
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St8sia6_sf AGGAAAATGCTGGCAGAAGA 
Ust_a CTCGGTTTCCAGTGGAGTTG 
Ust_sf ACCAGCGGATGAGATACGAG 
Xylt2_a CATGACATCACTGAGCCCAC 
Xylt2_sf TCGAGTCGACTGTGAACCAG 
a: antisense sf: sense Fluorescein labelled; Gene names as annotated on the ENSEMBL 
homepage (www.ensembl.org/index.html). 
 
Table 5.5.2 Oligonucleotides designed for cloning and RT-PCR
Cloning Sequence (5` - 3`)  Usage 
LMAN1-CRD_s PO4-GGACGGCGTGGGAGGA cloning in pET44a(+)  
LMAN1-CRD_a PO4-TCAGTGGACCGTAGACAAACATG   
LMAN1c_KpnI_s GTGGTACCAAGATGGCGGGATCCAGGC cloning in pcDNA3.1 
LMAN1c_NotI_a CCTGGCGGCCGCAGGAAAATGGTAGTCAAAAG   
   
RT-PCR      
LMAN1c_sf GCTCTCGATCTCCTACACTCTCA LMAN1 RT-PCR:  size: 122 bp 
LMAN1c_a GGAGGAATTTGAGCACTTTCA   
A1AT_s CGAAGAGGCCAAGAAACAGA A1AT RT-PCR Ex2-Ex4 size: 484 bp 
A1AT_a GACCTTAGTGATGCCCAGTTG   
XYLT2c_s TCGAGTCGACTGTGAACCAG XYLT2 RT-PCR  size: 298 bp 
XYLT2c_a AGGTAGCCCTGGAAATGGTC   
XYLT1c_Ex6 ATGCAAGGTTCATTCGGAAG XYLT1 RT-PCR  size: 250 bp 
XYLT1c_Ex8 CTTCCATACGGTCCTGGAGA   
GAPDH_s CCACCCAGAAGACTGTGGAT GAPDH RT-PCR  size: 119 bp 
GAPDH_a TTCAGCTCAGGGATGACCTT   
a: antisense; sf: sense Fluorescein labelled; c: coding region; PO4: 5`-phosphorylation for blunt 
end ligation; Ex: represents the oligonucleotide location regarding the exons. 
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5.6 Buffers 
Standard buffers used and not specifically mentioned in the method part (section 6). 
 
LB-medium 
 
10 g Trypton 
5 g Yeast 
10 g NaCl 
Ad 1000 ml H2O dest, adjust pH to 7.0, autoclave 
 
LB-Agar with ampicillin 
 
LB-medium 
2% Bacto-agar 
add 100 mg ampicillin per liter (100 µg/ml) 
 
RIPA buffer 
 
 
50 mM Tris base, adjust pH to 7.4 with HCl 
150 mM NaCl 
1% Triton-X-100 
1% Sodium desoxycholate 
0.1 mM CaCl2
0.1% SDS 
0.01 mM MgCl2
 
TBE electrophoresis buffer (10x)  
 
108 g Tris base 
55 g Boric acid 
40 ml 500 mM EDTA 
Ad 1000 ml H2O dest, adjust pH to 8.0 
 
TBS (1x)  
 
 
50 mM Tris base 
150 mM Sodium chloride 
1 M Hydrochloric acid (~ 9.5 ml) 
Ad 1000 ml H2O dest, adjust pH to 7.5 with HCl. 
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Lowry Buffer
 
Reagent A 
0.02% Cupper sulfate (CuSO4)
4% Sodiume carbonate (Na2CO3)
0.8% Sodium hydroxide (NaOH)
0.04% Potassium sodiume tartrate (KNaC4H4O6 •4 H2O) 
Reagent B 
Folin-Ciocalteu phenol reagent 5x diluted in H2O dest. 
 
Citrate Buffer (10 x) 
 
21.0 g Citric acid 
Ad 1000 ml H2O dest, adjust pH to 6.0 by the usage of NaOH platelets, store at 4°C. 
 
Potassium phosphate buffer  
 
 
50 mM K2HPO4
50 mM KH2PO4
Titration to pH 7.4. 
 
HBS-Buffer (10 x) 
 
 
140 mM NaCl 
50 mM HEPES 
750 µM Na2HPO4 
Adjust pH to 7.12. 
 
PBS (10 x) 
 
 
80 g Sodium chloride 
2 g Potassium chloride 
14.4 g Disodium hydrogenphosphate 
2.4 g Potassium dihydrogenphosphate 
Ad 1000 ml H2O dest, adjust pH to 7.2. 
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6. METHODS 
6.1 Molecular Biology methods 
6.1.1 Isolation of genomic DNA and RNA 
Genomic DNA was isolated from cancer cell lines and paraffin-embedded archival 
specimens after manual microdissection of tumor and corresponding normal tissues 
using the DNeasy Blood & Tissue kit. RNA was isolated using the RNeasy Mini kit. 
6.1.2 Oligonucleotide design 
Oligonucleotides for frameshift mutation analysis, sequencing analysis and cloning 
PCRs were designed by the usage of Primer 3.0 software. Oligonucleotides were 
purchased from Thermo Scientific in HPLC-purified quality. Oligo (dT) primers were 
used as suggested by the supplier. 
6.1.3 Standard Polymerase Chain Reaction (PCR) 
For a standard PCR approach taq DNA polymerase with appropriate buffers was 
used. For cloning PCRs the Phusion® High Fidelity taq polymerase was selected 
which exhibits 3` − 5` exonuclease activity for proof-reading (6.1.7). PCRs were 
performed in RoboCycler® Gradient 96 Temperature Cyclers from Stratagene.  
Cycling conditions for Taq DNA polymerase 
Step Number of cycles Temperature Time 
Initial denaturation 1 94°C 4 min 
Cyclic amplification   (1)  35 94°C 30 sec 
                                  (2)  58°C – 62°C 45 sec 
                                  (3)  72°C 1 min 
Final elongation 1 72°C 5 – 10 min 
(1) denaturation, (2) annealing, (3) elongation 
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Standard PCR pipetting scheme 
Component  Final Concentration  Volume  
Reaction buffer (10x) 1 x 2.5 μl  
MgCl2 (50 mM) 1.5 mM 0.75 µl 
dNTP-Mix (2 mM) 200 µM 2.5 μl  
Primer_sense (5µM) 0.5 µM 2.5 μl  
Primer_antisense (5µM) 0.5 µM 2.5 μl  
Taq DNA polymerase 5 U/µl  0.125 μl  
H2O HPLC-grade  - 13.125 μl  
Template DNA*  10 - 500 ng 1.0 μl  
Total volume - 25 µl 
* 10-20 ng for plasmid-DNA and 200-500 ng for genomic DNA 
6.1.4 Sequencing 
PCR products, like frameshift mutation fragments or cloned plasmids were 
sequenced using the BigDye Terminator v1.1 sequencing kit.  
The following reaction mix was used 
 Concentration  Volume  
Template1  -  10.0 μl  
BigDye Ready Reaction Mix  -  8.0 μl  
Sequencing Primer  5 μM  2.0 μl  
1Purified PCR product or plasmid (approx. 350 ng)  
The sequencing reaction was performed under identical conditions for all primers and 
templates used. In order to purify the obtained sequencing products, the products 
were precipitated with 10 μl 3 M sodium acetate (pH 4.5) and 250 μl of 100% EtOH 
and centrifuged at 13.000 rpm for 15 min at room temperature. The supernatant was 
discarded and the products were washed with 250 μl of 70% EtOH and centrifuged at 
13.000 rpm for 5 min at room temperature. The supernatant was again discarded and 
the pellets were dried for 4 min in a vacuum centrifuge to remove traces of EtOH. 
DNA pellets were afterwards resolved in 12 μl Hi-Di formamide and analyzed on an 
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ABI3100 genetic analyzer. The obtained results were evaluated with Sequencing 
Analysis software (Applied Biosystems, version 3.7). 
6.1.5 cMNR Frameshift mutation analysis 
Frameshift mutation analyses were performed on genomic DNA of cell, tumor and 
blood samples derived as mentioned in chapter 6.1.1. For frameshift mutation 
analysis on tumor genomic DNAs (gDNAs) oligonucleotides were designed to obtain 
short amplicons of about 100 bp, thus allowing robust amplification from archival 
tissues. Sense primers were Fluorescein labelled (sf; Table 5.5.1). PCR was 
performed as described in 6.1.2. PCR fragments were analysed in 2% agarose gels 
and subsequently on an ABI3100 Genetic Analyzer. Size, height and profile of 
microsatellite peaks were analyzed using Sequencing analysis software (version 
3.7). Coding microsatellite instability was scored if smaller or larger-sized amplimeres 
were detected in tumor DNA compared to DNA from normal tissue. Frameshift 
mutations were confirmed by DNA sequence analysis. 
6.1.6 Reverse transcription PCR 
One microgram of total cellular RNA was reverse transcribed using Superscript II 
reverse transcriptase according to the manufacturer’s instructions. Primers for the 
LMAN1 gene were designed to flank the A9 cMNR and spanned exon 8 and exon 9 
to exclude amplification from genomic DNA. Primers for the XYLT2 gene were 
designed to flank the C7 cMNR. PCR products were visualized on ethidium bromide-
stained 2% agarose gels. All cell lines were examined by frameshift mutation 
analysis on cDNA for comparison with genomic DNA mutation data. Mutations were 
confirmed by DNA sequence analysis. As a control for loading and integrity of mRNA, 
reverse transcription-PCR (RT-PCR) analysis of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was performed. Table 5.5.2 presents the primers designed 
for RT-PCRs of LMAN1, XYLT2, XYLT1, A1AT and GAPDH. 
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6.1.7 Restriction digest 
Restriction enzymes cut double stranded or single stranded DNA at specific 
restriction sites. The activity of restriction enzymes depends on their sequence 
specificity and cofactor requirements. Many techniques such as cloning, mutational 
analysis, probe preparation and linearization before stable transfection require the 
use of restriction digests. One unit of restriction enzyme will completely digest 1 µg of 
substrate DNA in a volume of 50 µl in 60 min, for most enzymes at 37°C in a water 
bath. Restriction enzymes were received from New England Biolabs, Roche or 
Promega (see section 5). 
Below a typical restriction digest is depicted 
Restriction Enzyme 1 Unit 
DNA 1 µg 
10 x Restriction buffer 5 µl (1x) 
BSA 100 µg/ml (1x) if sufficient 
Total Reaction 50 µl 
Incubation Time 1 hour 
Incubation Temperature enzyme-dependent 
6.1.8 Cloning of DNA fragments 
Preperation of vectors and inserts 
During cloning experiments a DNA fragment (e.g. gene of interest GOI) is inserted 
into a suitable vector for downstream protein expression of the GOI. The coding 
sequence of LMAN1 was PCR-amplified from cDNA with primers introducing KpnI 
and NotI restriction sites for cloning full length LMAN1 into the pcDNA3.1-vector. Wild 
type cDNA of LMAN1 was amplified according to the Phusion PCR program using 2 
μl of cDNA derived from the LMAN1 wild type cell line SW948 as a template. LMAN1-
CRD was PCR-amplified from LMAN1-pcDNA3.1 vector with 5`-phosphorylated 
primers for blunt end cloning into the pET44a(+) vector. Both constructs are outlined 
in Figure 6.1, presenting important amino acid (aa) residues for the transport function 
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of LMAN1 and the location site of the cMNR. For the amplification of LMAN1-CRD, 2 
ng of plasmid DNA were used. The XYLT2-pcDNA3.1 vector was a kind gift of Dr. 
Hans Bakker (Medizinische Hochschule Hannover). The obtained PCR products 
were visually controlled on 1 – 2 % agarose gels and purified by gel extraction using 
the JETQuick Gel Extraction Spin Kit. The purified PCR product of full length LMAN1 
was digested with KpnI and NotI (see 6.1.7), creating “sticky ends” to ensure the 
appropriate orientation of the insert in the vector after ligation. 
 
Figure 6.1 LMAN1 constructs [Hauri et al., 2000]. A. Full length LMAN1 
used for mammalian protein expression and B. presenting the LMAN1-CRD 
with oligomerization domain and N-terminal fusion domains for expression in 
bacteria. In both constructs the location of the LMAN1 cMNR is shown (A9 ? 
K302-304). Double lysines in C-terminal position (K507+K508) are required 
as ER-retention motif the double phenylalanine motif (F509+F510) is an ER-
exit determinant. Disulfide linked oligomerization is mediated by two luminal 
cysteine residues C466 and C475. D121 and N156 are two conserved 
residues required for the interaction with Ca2+ ions and the monosaccharides 
over hydrogen bonds. H 178, acts as a pH-sensor, is necessary for Ca2+ 
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binding and substrate release in the ERGIC because of a more acidic 
environment [Zhang et al., 2009]. SP: signal peptide; CRD: carbohydrate 
recognition domain; NusA: fusion tag; His: histidine tag; TMD: 
transmembrane domain; CD: cytosolic domain. 
Pipetting instruction for Phusion-Tag polymerase 
Component  Concentration  Volume  
Reaction buffer 5 x stock  4.0 μl  
dNTP-Mix  10 mM  0.4 μl  
Primer_sense  5 μM  2.0 μl  
Primer_antisense  5 μM  2.0 μl  
Phusion DNA polymerase  2 U/μl  0.2 μl  
H2O HPLC-grade  - 9.4 μl  
Template DNA*  10 - 500 ng/μl 1.0 μl  
* 10-20 ng for plasmid-DNA and 200-500 ng for genomic DNA 
Cycling conditions for Phusion-Tag polymerase 
Step Number of cycles Temperature Time 
Initial denaturation 1 98°C 30 sec 
Cyclic amplification   (1)  25 – 35  98°C 5 – 10 sec 
                                  (2)  58°C – 62°C 10 – 30 sec 
                                  (3)  72°C 15 – 30 sec/1kbp 
Final elongation 1 72°C 5 – 10 min 
(1) denaturation, (2) annealing, (3) elongation 
Vector pcDNA3.1 was also digested with KpnI and NotI and purified by gel extraction. 
For the blunt end cloning of LMAN1-CRD pET44a(+) vector was digested with PshAI 
and dephosphorylated using the calf intestinal phosphatase (CIP) to prevent self-
ligation. One unit CIP dephosphorylates 1 pmol 5`- terminal phosphorylated DNA 
fragments in 60 min at 37°C. 
Calculation for the dephosphorylation of 10 µg (10 x 10-6g) digested plasmid 
MW of one nucleotide (1bp)  = 330 g/mol 
MW of pET44a(+) single stranded = 7311 bp = 2.412.630 g/mol  
MW of pET44a(+) double stranded = 4,82526 x 106 g/mol  
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10 x 10-6 g / 4,75215 x 106 g/mol  = 2,1 x 10-12 mol 
As a double stranded DNA fragment possessed two 5`- ends the pET44a(+)- vector 
contains altogether 2.1 pmol 5`-ends. 2.1 units CIP were required to dephosphorylate 
10 µg of pET44a(+) vector. 
 
Procedure 
Step Component Incubation Time 
10 µg digested vector DNA 
3 units CIP 
5 µl 10 x CIP buffer 
Dephosphorylation
Total volume 50 µl 
1 hour at 37°C  
(water bath) 
Heat inactivation 200 mM EGTA 10 min 75°C 
Ligation 
After restriction digest and dephosphorylation steps vector and PCR product were 
ligated at a molar ratio of vector-DNA to insert-DNA of 1 : 3. The ligation catalyzes 
the formation of phosphodiester bonds between a 5`-phosphate and a 3`-hydroxyl 
terminus in a digested double DNA strand. Blunt end ligation was performed at 16°C 
and sticky end ligation at 4°C over night with T4-ligase and the appropriate 10 x 
reaction buffer. As a re-ligation control vector without insert underwent the same 
procedure.  
Calculation of the molar amounts of PCR products and vectors  
DNA amount (mol) = weight (g) / (660 g/mol x bp) 
Transformation into bacteria 
After ligation the ligation reactions are transformed into bacteria for the production of 
plasmid-DNA. Chemically competent DH5α-cells were stored at – 80°C and thawed 
on ice directly prior to use. 2 μl of a ligation reaction was added and gently stirred. 
The mixture was incubated on ice for 30 min followed by a heat-shock in a water bath 
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at 42°C for exactly 30 seconds and storage on ice for 2 min. Subsequently, 250 μl 
pre-warmed SOC-medium was added to the transformation reaction and mixed. After 
1 hour incubation at 37°C in a shaking incubator 50 μl to 100 μl of each 
transformation reaction were plated on agar plates containing 100 µg/ml ampicillin, 
used for the positive selection of bacteria that had taken up the vector during 
transformation. Grown clones were checked by Colony-PCR with insert-specific 
primers and only clones containing the insert as determined by gel electrophoresis 
were used for the isolation of plasmids. For Colony-PCR bacterial clones were picked 
into a reaction tube containing water and were heated for 10 min at 95°C. 2 µl of 
bacteria solution was used in a Standard-PCR described in 6.1.2. Positive clones 
were grown in 5 ml over-night cultures LB medium (100 µg/ml ampicillin) at 37°C.  
Plasmid preperation 
Plasmids were purified from 4 ml of the 6 ml over-night culture using the NucleoSpin 
Plasmid kit according to the manufacturer’s instructions. Cloned insert cDNAs of 
LMAN1 or LMAN1-CRD in the plasmid-preparation were verified by direct 
sequencing (6.1.3) of overlapping fragments before starting transfection or 
expression experiments. For transfection of plasmid-DNA into mammalian cells, 
bacteria were grown in 100 ml over-night cultures and plamids were purified under 
endotoxin-free conditions using the Endo-free Plasmid Maxi kit. 
Cryopreservation of positive bacteria clones 
For long term storage, bacteria were cryo-preserved by mixing 1 ml of cultured 
bacteria with 250 μl glycerol and storage at –80°C. 
6.2 Biochemical methods 
6.2.1 Determination of protein concentration 
Bradford Assay 
The Bradford protein assay is based on an absorbance shift in the dye Coomassie  
brilliant blue G. Coomassie binds to basic (e.g. arginine) and aromatic amino acid 
(aa) residues of proteins thereby shifting itsabsorbance from 465 nm to 595 nm. The 
increase of absorbance at 595 nm is proportional to the protein concentration present 
 90
                                                                                                                                                     Methods 
in the sample. Bovine serum albumin was used as a standard (0, 1, 2, 5 and 10 
µg/ml) protein sample was 10 x diluted in H2O dest. The Bradford Assay was 
performed using the BioRad Protein assay reagent according to manufacturer`s 
instructions. 
Lowry Assay 
The Lowry protein assay is based on Cu+-ions binding to peptide bonds under 
alkaline conditions with the oxidation of aromatic protein residues. Cu+ -ions build an 
unstable blue complex with the yellow Folin-Ciocalteau phenol reagent proportional 
to the protein concentration present in the sample. The concentration of the reduced 
Folin reagent is measured by absorbance at 630 nm [LOWRY et al., 1951]. Protein 
standards and protein samples were used as described above. After precipitation of 
proteins with an equal volume of 10% TCA (Trichloroacetic acid), pellets were solved 
in 50 µl 200 mM NaOH at 65°C for 10 min. Proteins were first incubated with 500 µl 
reagent A (5.6) for 20 min at room temperature, followed by an incubation step with 
500 µl reagent B (5.6) for 30 min at room temperature.  
For both methods the protein absorbance was measured using the 
Ultrospec™ 3300 pro UV/Visible Spectrophotometer. 
6.2.2 Polyacrylamide Gelelectrophoresis 
Cell pellets were lysed in RIPA-buffer, sonicated and subsequently ultracentrifugated 
at 430.000 g for 15 min at 4°C (Beckmann TLA 100.2 rotor). Protein concentration 
was determined using the Bradford or Lowry method (6.2.1) and 13 to 65 µg protein 
was incubated in NuPAGE LDS Sample Buffer at 95°C for 5 min. Proteins were 
separated using NuPAGE® Bis-Tris Mini gels from Invitrogen (acrylamide 
concentration 4 – 12%; 1.0 mm x 12 well). The NuPAGE® System is based on a Bis-
Tris-HCl buffered (pH 6.4) polyacrylamide gel, with a separating gel that operates at 
pH 7.0. Denatured protein was loaded together with a molecular weight marker. For 
Western blot analysis the SeeBlue® Plus Pre-stained protein standard and for silver 
gels the Mark12TM unstained standard were applied. As running buffer NuPage MES 
running buffer was used. For run conditions the manufacturer`s instructions were 
followed.
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6.2.3 Western blot analysis  
Protein preparation and separation was perormed as mentioned in 6.2.4. Protein 
concentration was determined by Lowry method (6.2.1). 65 µg of protein was 
seperated as described in 6.2.2 followed by Western blot analysis using primary 
antibody directed against LMAN1 or as a control anti-actin antibody. Horseradish 
peroxidase (HRP) – conjugated antibodies were used as secondary antibodies (Anti-
Rabbit IgG or Anti-Mouse IgG; see 5.4). Visualization was performed with Western 
Lighting Chemiluminescence Reagent Plus on Kodak BioMax light films. 
6.2.4 Silver staining of polyacrylamide gels 
Silver staining is the most sensitive method for permanent visible staining of proteins 
in polyacrylamide gels with a detection limit of 1 – 5 ng protein. Silver ions (Ag+) build 
complexes with Glu-, Asp- and Cys-residues of proteins. By treatment with 
formaldehyde, Ag+-ions are reduced and form an insoluble brown precipitate of 
metallic silver. 65 µg of protein was separated as described in 6.2.2 and 
subsequently stained as described below. All solutions were prepared in H2O dest 
and complete staining protocol was performed at room temperature. Gels were 
preserved in Gel-DryTM-Drying solution for long-term storage. 
Solutions 
Fixing solution 
Fixation 1 Fixation 2 Fixation 3 
10% (v/v) 96% acetic acid 5%(v/v) 96% acetic acid 10%(v/v) ethanol absolute  
40%(v/v) methanol  10%(v/v) ethanol absolute   
  
  
Sensitizing solution Silver solution 
0.02% (w/v) Na2S2O3 0.2% (w/v) AgNO3
0.02% (v/v) 37% formaldehyde  
  
  
  0.05% (v/v) 37% formaldehyde  
  
  
Developing solution Stop solution 
6% (w/v) Na2CO3 10% (v/v) 96% ethanol 
0.4% (w/v) Na2S2O3
0.02% (v/v) 37% formaldehyde 
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Staining protocol  
Staining solution Repeats Incubation time 
Fixation 1  1 x 1      h 
Fixation 2 1 x 30    min 
Fixation 3 1 x 15    min 
H2O dest 3 x 1      min 
Sensitizing solution 1 x 1      min 
H2O dest 1 x 1      min 
Silver solution 1 x 15    min 
H2O dest 3 x 20    sec 
Developing solution   1 x 5-10 min†
H2O dest 3 x 1      min 
Stop solution 1 x 15    min 
H2O dest 3 x 5      min 
Gel-Dry Drying solution 1 x 15    min* 
 
†  Monitor development and change the solution when protein bands are visible and the 
background is just starting to darken. 
*  Gels were placed between two cellophane sheets and spanned into a frame for drying 
over night at RT. 
6.2.5 2D-gel electrophoresis 
During the 2D-gel-electrophoresis proteins are separated by isoelectric focusing 
followed by a molecular weight separation. For the first dimension proteins were 
dissolved in an appropriate buffer (8 M urea, 2% CHAPS, 0.002% Bromophenol 
Blue, 0.5% ZOOM® Carrier Ampholytes pH 3 -10 non-linear) for isoeletric focusing 
containing ampholytes. Ampholytes are small, soluble molecules with positive and 
negative charged groups, which sort based on their isoelectric points in an electric 
field. Isoelectric focusing was established in a ZOOM® IPG Runner cassette 
according to manufacturer´s instructions. For the second dimension focused IPG 
stripe was loaded into a NuPAGE® Bis-Tris Mini gel together with a molecular weight 
marker (6.2.2) and proteins were separated by molecular weight. The manufacturer`s 
instructions were followed.
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6.2.6 Protein expression and purification 
6.2.6.1 Bacterial expression 
LMAN1-CRD was blunt end cloned as described in 6.1.7. The gene product included 
aa 31 – aa 480 of full length LMAN1 protein (see Fig. 3.15). The pET-44 vectors are 
designed for cloning and high-level expression of peptide sequences fused with the 
495 aa NusA-Tag™ protein and encode an additional N-terminal His-Tag. NusA (N 
utilization substance A) is a fusion protein that itself has a high solubility thus 
enhancing the solubility of the fusion partner, LMAN1-CRD. E. coli lysogenic strain 
BL21 (DE3) cells were used for plasmid expression and grown in terrific broth 
medium (TB) for liquid culture. Media contained 100 µg/ml ampicillin. 1 litre of shake-
flask culture was incubated at 37°C for constitutive expression of LMAN1-CRD 
construct. Protein expression was induced by 100 µM IPTG (final concentration) in 
the exponential growing phase (OD = 0.6 – 0.7) and culture was grown over night. 
Bacteria were harvested by centrifugation (3000 rpm, 30 min, 4°C; Sorvall) and after 
cell lysis (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.5 mM EDTA, 5% (v/v) glycerol, 1 
mM TCEP and Lysonase Bioprocessing Reagent 20 µl/1g cell paste), a series of 
detergent and buffer washes removed membrane components and contaminating 
proteins from the IB pellet (see Novagen User Protocol). Purified IBs were denatured 
with the reducing agent Tris-(2-carboxyethyl)-phosphine HCl (TCEP) and the 
detergent N-Laurosylsarcosine followed by dialysis (10 mM Tris-HCl, 50 µM EDTA, 
100 µM TCEP, 0.06% N-Laurosylsarcosine solution, pH 8.0) and subsequent testing 
of different refolding conditions using the iFOLD™ Protein Refolding System 1. The 
iFOLD™ Protein Refolding System 1 provides reagents for inclusion body (IB) 
purification and denaturation, combined with a plate-based protein refolding buffer 
matrix. One 96-well plate contains 92 unique refolding solutions (see Novagen user 
protocol). 92 refolding conditions were checked by a radioactive binding assay with 
A1AT-125I (6.3.2). Eight refolding conditions showed high binding capacity and were 
further analysed (Tab 6.1). 
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Table 6.1 iFOLD buffer compositions for 8 buffers showing high binding capacity for LMAN1 
iFold buffer 1 iFold buffer 2 
50 mM Tris pH 7.0 (RT) 50 mM Tris pH 7.0 (RT) 
12.5 mM β-Cyclodextrine 100 mM NaCl 
1 mM TCEP 1 mM CaCl2
0,5 M Guanidine-Hydrochloride (GuHCl) 1 mM MgCl2   
  12.5 mM β-Cyclodextrine 
 
iFold buffer 3 iFold buffer 4 
50 mM Tris pH 7.5 (RT) 50 mM Tris pH 7.5 (RT) 
100 mM NaCl 100 mM NaCl 
1 mM TCEP 0.5 M Guanidine-Hydrochloride (GuHCl) 
0.1% PEG-6000 (w/v)   
    
iFold buffer 5 iFold buffer 6 
50 mM Tris pH 7.5 (RT) 50 mM Tris pH 8.0 (RT) 
250 mM NaCl 12.5 mM β-Cyclodextrine 
12.5 mM β-Cyclodextrin 0.5 M Guanidine-Hydrochloride (GuHCl) 
0.1% PEG-6000 (w/v)   
  
   
iFold buffer 7 iFold buffer 8 
50  mM Tris pH 7.5 (RT) 50 mM Tris pH 7.5 (RT) 
100 mM  NaCl 100 mM NaCl 
12.5 mM β-cyclodextrine 12.5 mM β-cyclodextrine 
0.1% PEG-6000 (w/v) 1 mM TCEP 
  0.5 M L-Arginin-Hydrochloride (L-Arg) 
Previous to refolding, LMAN1-CRD was purified over Ni2+-Sepharose using the N-
terminal His-tag of the construct (section 6.2.2.3). N-terminal NusA- and His-tags 
were afterwards removed by Enterokinase. Digested protein was refolded over night 
by room temperature using the best refolding conditions. The pre-purified, digested 
and refolded LMAN1-CRD protein was functionally purified using either mannose- or 
A1AT-sepharose. 
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6.2.6.2 Mammalian protein expression 
293T cells were transiently transfected by the CaPO4-method, gene product was 
expressed for 48 hours and cells were harvested under native conditions using 
Triton-X-100 as detergent. Cells were harvested using trypsin and centrifuged for 
pelleting at 1200 rpm, 10 min at RT. Cells were lysed under native conditions using 
Triton-X-100 as detergent (cell lysis buffer: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 
mM CaCl2, 1% Triton-X-100), sonicated and ultracentrifuged at 430.000g 4°C for 15 
min (UZ, Beckmann). Supernatant was dialysed against the same buffer containing 
0.04% Triton-X-100. Dialysed protein lysate (dialysis buffer: 20 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1 mM CaCl2, 0.4% Triton-X-100) was functionally purified over 
mannose-sepharose. 
6.2.6.3 Protein purification with ÄktaPurifier FPLC System 
For purification of proteins Ni2+-sepharose self-packed mannose-sepharose or self-
packed A1AT-sepharose were used. All protein solutions were purified using the 
ÄktaPurifier FPLC system.  
His-FPLC conditions 
Column was equilibrated using 2 column volumes (CV) washing buffer and protein 
solution was either loaded over the Superloop or the syringe, depending on protein 
solution volume. A flow rate of 0.5 ml/min was used (maximal pressure: 0.6 MPa). 
Bound protein was washed with 5 CV washing buffer and eluted with 5 CV elution 
buffer. Fractions were separated on a 4 – 12% Bis-Tris Gel and analysed by Western 
blot (6.2.1) using primary antibody directed against LMAN1 or by silver staining 
(6.2.2). 
His-FPLC washing buffer His-FPLC elution buffer 
50 mM Tris-HCl pH 7.4 50 mM Tris-HCl pH 7.4 
200 mM NaCl 200 mM NaCl 
1 mM CaCl2 1 mM CaCl2
20 mM Imidazole 500 mM Imidazole 
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Mannose- and A1AT-FPLC conditions 
Column was equilibrated using 2 CV washing buffer and protein solution was either 
loaded over the Superloop or the syringe, depending on protein solution volume. A 
flow rate of 0.1 ml/min was used (maximal pressure: 0.6 MPa). Bound protein was 
washed with 5 CV washing buffer and eluted with 5 CV elution buffer. Mannose- and 
A1AT-buffers were sampled for both sepharoses. Fractions were separated on a 4 – 
12% Bis-Tris Gel followed by Western blot analysis (6.2.1) using primary antibody 
directed against LMAN1 or by silver staining (6.2.2). 
 
Mannose FPLC washing buffer Mannose FPLC elution buffer 
20 mM Tris pH 7.4 (4°C) 20 mM Tris pH 7.4 (4°C) 
150 mM NaCl 150 mM NaCl 
1 mM CaCl2 1 mM CaCl2
0.04% Triton-X-100 0.04% Triton-X-100 
- 20 mM EGTA 
- 100 mM Mannose 
 
A1AT FPLC washing buffer A1AT FPLC elution buffer 
10 mM HEPES pH 7.4 (4°C) 10 mM Tris pH 7.4 (4°C) 
10 mM MES  150 mM NaCl 
150 mM NaCl 0.04% Triton-X-100 
1 mM CaCl2 20 mM EGTA 
0,04% Triton-X-100 - 
6.2.7 Alpha-1-antitrypsin ELISA 
Cells were grown in T25-flasks to approximately 80% confluence (corresponding to 
approximately 7 µg DNA) and conditioned cell culture medium was harvested after 
24 h. For the Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) 100 µl undiluted 
conditioned medium was used. ELISA was established according to manufacturer´s 
instructions.  
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6.2.8 ER-Golgi Fractionation 
ER-Golgi fraction was isolated using the Endoplasmic reticulum isolation kit. The kit 
is based on a differential centrifugation step for the isolation of the ER. Complete 
Post Mitochondrial Fraction (PMF) was established according to manufacturer´s 
instructions. Pulse Chase Experiments were performed using a defined protein 
amount of whole PMF fractions. 
6.3 Radioactive labelling  
6.3.1  Liquid scintillation counting (LSC) 
Liquid scintillation counting is a standard technique for measuring radiation (α-, ß and 
-radiation). The radiolabelled sample is incorporated into uniform distribution with a 
liquid chemical medium capable of converting the kinetic energy of nuclear emissions 
into light energy. Ultima Gold was used as a liquid chemical medium. Ultima Gold is 
a liquid scintillation cocktail for a wide range of aqueous and non-aqueous samples. 
Aromatic molecules (scintillators) in LSC cocktails are excited by radiation, 
recognized by scintillation or light emission respectively. Actually pi-electrons in 
aromatic molecules are easily excited and are able to convert and transfer energy. 
By mixing the Ultima Gold solution with the radiolabelled sample the energy of 
radiation, which is the nuclear decay in form of particles emitted freely, is converted 
into excitation energy. After transfer of energy to a primary scinitillator molecule, the 
excited molecule emits light in the range 300 – 400 nm and transits into the ground 
state energy. Emitted light is absorbed by secondary scintillator molecules and 
delivered as fluorescent light with a wavelength of 400 nm – 470 nm. Fluorescent 
light is converted into electrical impulses by photo multipliers (PMT tubes) and 
subsequent translated into a measurable value (counts per minute CPM). Dpm 
calculations were based on the tSIE-method. 
6.3.2 LMAN1 binding to 125I−A1AT 
Radioactive iodine (125I) was incorporated into alpha-1-antitrypsin (A1AT) by 
electrophilic substitution using Pierce ® Iodination Beads. Tyrosine residues of 
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human A1AT were radioactively labelled by the chosen method. First 125I was 
incubated with iodination beads to be in the oxidized form and subsequent positive 
charged iodine reacts with tyrosines to form 125I- tyrosine. 100 µg pure A1AT protein 
(in Tris, NaCl pH 7.8; 10 mg/ml each) was incubated with 74MBq 125I and potassium 
phosphate buffer [Markwell, 1982]. Functional LMAN1-CRD binding was verified by 
the constructs specificity. The N-terminal His-tag of the LMAN1-CRD construct is 
able to bind Ni2+-sepharose whereas functional binding over the LMAN1 CRD-
domain should be performed by A1AT-125I (Fig.6.2).  
 
Figure 6.2 Radioactive binding assay for verification of functional 
LMAN1 binding. In case of LMAN1 CRD binding to its substrate A1AT, 
which was iodinated by 125I, radioactivity could be measured in the elution 
fraction. Bound protein was eluted by 1 M imidazole. 
25 µl Ni2+-sepharose were incubated with radioactive 125I -A1AT (100.000 CPM) and 
refolded protein lysate (92 different buffer conditions; iFold System) for one hour at 
4°C. After washing steps bound protein was eluted using 1 M imidazole. Radioactivity 
in the eluted fractionmeasured with UltimaGold in a liquid scintillation counter (LSC 
TRI-CARB 2900 TR) indicates 125I-A1AT binding. Non-specific binding of 125I-A1AT to 
the agarose was detected in control experiments applying 1M imidazol as 
competitive inhibitor of specific binding.  
6.3.3 Metabolic labelling with 3H–Xylose  
HDC9 cells were transiently transfected with either the empty vector control or 
XYLT2-pcDNA3.1 as described in 6.4.3.1 and 24 hours after transfection cells were 
fed with RPMI-medium containing 5 µCi 3H-Xylose. After 48 hours incorporation time 
cells were harvested with 0.9% NaCl and trypsin. Cells were centrifuged at 4000 rpm 
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for 5 min RT and cell pellet was dissolved in 1 N NaOH for 1 hour at 56°C, sonicated 
and subsequently neutralized in 2.5 N acetic acid. One part was mixed with 10 ml 
Ultima Gold and measured in a LSC. For the other part protein concentration was 
measured using the Lowry method. Results were evaluated as decay per minute for 
a given protein amount in mg. 
6.3.4 Pulse Chase Experiment  
Six million parental LoVo cells or LMAN1-transfected LoVo cells were sowed in 10-
cm dishes with methionine-free medium containing 10% dialysed FCS and 1% 
glutamine. After 24 hours cells were pulsed with the same medium containing 
100µCi/ml 35S-methionine. After 30 min chase time cells were harvested and 
fractionated using the Endoplasmic Reticulum Isolation Kit (6.2.8). 30 µg isolated 
ER/Golgi proteins (PMF; between 1.000.000 to 500.000 DPM) were separated by 2-
D gel electrophoresis (6.2.5) using a nonlinear pH-gradient from 3 – 10 as first 
dimension and 4 – 12% polyacryamide gel were used in the second dimension. Gels 
were fixed in fixation solution 1 (10% (v/v) 96% ethanole, 2.5% (v/v) methanole in 
H2O dest) for 1 hour or over night at room temperature. After washing steps in 
distilled water (H2O dest) gels were fasten-dried on whatman filter papers using 
undertow, afterwards dried gels were exposed to a phosphoimager screen for 1 
week. During phosphorimaging radioactive material can be localized and quantified 
on an imaging plate (IP). IPs are coated with barium fluoro-halide phosphor crystals 
(BaF(Br,I):Eu2+). Europium crystals (Eu2+) within the IP stored emitted radiation of 
35S-proteins on 2-D-gels in form of trapped electrons with an absorption band at 
about 600 nm. Exposed IP was scanned with a He-Ne (633 nm) laser within the FLA-
3000 Phosphorimager, released electrons were recombined with Eu2+ crystals 
releasing photons at 400 nm. The blue light (400 nm) emitted was collected by 
Phosphorimager software producing a digitized image (FLA3000 settings: Sample 
Mode IP; gradiation 256 (8bit); resolution 100 pixel). Digitized images were evaluated 
using the Proteomweaver Software for 2-D gel analysis (2004 Version 3.0.0 beta; 
Definiens AG, Munich, Germany). Proteomweaver software helps in precise verifying 
specific spots on 2-D gel images. 
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6.4 Cell Culture experiments 
6.4.1 Human cancer cell lines 
Most of the MSI-H CRC cell lines were either obtained from ATCC (Manassas, VA, 
USA) or the German Cancer Research Center (DKFZ, Heidelberg, Germany). Cell 
line Vaco6 was a kind gift of J.K.V. Wilson, Cleveland. The MSI-H CRC cell line 
K073A was established in our laboratory. MSI-H status of all colorectal tumor tissues 
used in the present study (n = 170) has been determined previously using the 
National Cancer Institute/ICGHNPCC reference marker panel including BAT25 and 
BAT26 [Boland et al., 1998] and one additional mononucleotide marker CAT25 
[Findeisen et al., 2005].  
6.4.2 Cell culture 
All cell lines were grown under standard conditions in RPMI 1640 supplemented with 
10% FCS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin in a humified incubator 
with 5% CO2 at 37°C. Depending on the cell growth, cells were subcultured twice a 
week at a ratio of 1:5 to 1:20, in order to keep the confluence of the cells between 
approximately 50% and 80%. Mycoplasma contamination of cultured cells was 
excluded by PCR. For cryopreservation, tumor cells were harvested and frozen at     
-80°C. Typically, 1 x 107 to 3 x 107 cells were stored in cryo-vials with 1.5 ml of 10% 
DMSO in FCS. 
6.4.3 Transfection methods 
6.4.3.1 Electroporation 
Tumor cells (n = 107) were transiently transfected by electroporation using the Amaxa 
Nucleofector 1, program T-20 with solution V and 5 µg DNA (program and solution 
dependent on cell line, see User manual). Because of a high mortality rate during 
electroporation medium was changed after 24 hours. Cells were grown in small 
plastic flasks (T25) and pelleted cells or conditioned medium were harvested after 24 
to 48 h. This method was used for transient transfection of Colo60H and HDC9 cells. 
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6.4.3.2 Lipofection 
One day before transfection, 0.5 to 2 x 105 cells (LoVo cells 2 x 105) were plated on 
24-well plate in 500 μl of growth medium without antibiotics so that cells had a 
confluency of 90 – 95% at the time of transfection. For each transfection sample 
complexes were prepared as follows: DNA was diluted in 50 μl DMEM medium 
without serum in Eppendorf tubes. Lipofectamine™ 2000 was gently mixed before 
usage, then the appropriate amount (ratio DNA : Lipofectamin 1 : 2.5) was diluted in 
50 μl DMEM and incubated for 5 minutes at RT in polystyrole tubes. Afterwards, 
diluted DNA was combined with diluted Lipofectamine™ 2000 (total volume = 100 μl). 
Complex formation was incubated for 10 min at RT. 100 μl of complexes were 
pipetted drop-wise to each well containing cells and medium. Cells were incubated at 
37°C for 18 – 48 hours prior to testing for transgene expression. Medium was 
changed after 4 – 6 hours.  
For generating stable cells, cells were selected with G418 (neomycin 
resistance) 24 – 48 hours after transfection. Appropriate concentration of G418 was 
tested prior to transfection. For LoVo cells the selection was performed using 400 
µg/ml G418. Treatment with G418 was continued for a minimum of 14 days. After the 
selection period, single clones were picked by scraping with a sterile pipet tip and 
transferred on 48-well plates. Alternatively, the cells were harvested by trypsination 
and limiting dilution of the bulk culture was performed for the selection of single cell 
clones on 96-well plates.
 102
                                                                                                                                                     Methods 
6.4.3.3 CaPO4 transfection 
293T cells were cultured in ten 10 cm dishes to a confluence of approximately 80%. 
For each transfection 1 ml 1 x HBS buffer, 10 µg plasmid DNA and 50 µl 2.5 M CaCl2 
were used. LMAN1-pcDNA3.1 was mixed with HBS buffer in a polystyrole tube, 
CaCl2 was added to the bottom of the tube and mixed by rotating the tube until 
disappearing of lines. Complex formation (precipitate) was incubated for 5 min. 
Calcium phosphate forms an insoluble precipitate with DNA, which attaches to the 
cell surface and is taken up by the cells via endocytosis [Jordan et al., 1996]. Formed 
Calcium phosphate/DNA precipitate was incubated on 293T cells for 10 min at RT. 
Subsequent culture medium was added and cells were incubated for 48 h in 37°C 
with 5% CO2, after 24 h medium was changed. 
6.4.4 Cell Proliferation Assay 
100 µl 5 x 104 cells/ml were sowed into a 96-well plate. Parental LoVo cells and 
mock-transfected as well as LMAN1-transfected LoVo cells were included. After one, 
two, and four days cell viability and growth was determined by adding 20 µl 
MTS/formazan. The MTS tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is bio-reduced by cells into 
a colored formazan product that is soluble in tissue culture medium. The quantity of 
formazan product as measured by the absorbance at 490 nm is directly proportional 
to the number of living cells in culture. MTS/formazan substrate was incubated in the 
cell medium for exactly one hour at 37°C and 5% CO2. Absorbance was measured at 
485 nm in an ELISA-Reader. Cells were measured in triplets and mean values were 
charted against time in days. 
6.4.5 Lectin-FACS analysis 
For cell surface glycan profiling a fluorescence-activated cell sorter (FACS) was 
used. FACS analysis distinguishes cells based on size and granularity as well as 
fluorescence. A laser beam is directed on a stream of fluid containing stained cells 
for analysis. By cells passing the beam, the beam light is scattered and fluorescent 
chemicals are excited. Cells can be determined by cell volume (FCS Forward 
 103
                                                                                                                                                     Methods 
scatter), granularity (SSC Side Scatter) and by fluorescence (f.e. filters for GFP and 
Phycoerithrin PE). Quantitative determination of carbohydrate-dependent lectin 
binding using streptavidin ⁄ R-phycoerythrin as a fluorescent marker was performed 
by flow cytofluorometry in a FACSCalibur instrument using the CellQuest pro 
software (Becton-Dickinson). Solutions with 4 x 105 cells per sample were carefully 
washed with PBS and incubated with biotinylated lectins for 30 min at 4°C. After 
washing steps in 1 x PBS/0.1% BSA cells were incubated with streptavidin ⁄ R-
phycoerythrin (1 : 40). LoVo cells without staining and LoVo cells incubated with 
streptavidin ⁄ R-phycoerythrin were used for adjusting the parameter settings of 
FACSCalibur. Mean fluorescence intensity was normalized to control values. 
Statistical analysis was performed on four independent experiments using Student’s 
t-test (independent by groups; grouping variable 0=mock-transfected LoVo cells; 
1=LMAN1-transfected LoVo cells) calculated with the program STATISTICA (v7.0 
Stat Soft.Inc; Tulsa. OK, USA).  
6.5 Human tissues 
Human tissues were obtained from the local tissue bank established within the 
German Collaborative Group on HNPCC. Informed consent was obtained from all 
patients and the study protocol was approved by the local Ethics Committee. Human 
tissues were formalin-fixed and paraffin-embedded (FFPE) and sections of 2 µm for 
immunohistochemistry and 5 µm for microdissection were used. 
6.5.1 Immunohistochemistry 
For immunohistochemical staining, 2-µm FFPE sample sections were deparaffinized 
and rehydrated. For antigen retrieval, slides were boiled in 10 mmol/L citrate buffer 
(pH 6) for 3 x 5 min and endogenous peroxidase activity was blocked with hydrogen 
peroxide (0.6%) for 20 min. Slides were rinsed with deionized water and then washed 
in PBS/0.1% Tween 20 (PBS-T) for 5 min. The slides were then stained by 2-h 
incubation at room temperature with anti-LMAN1 primary antibody (1:200) in 1% 
horse serum/PBS-T. A biotinylated anti-mouse/anti-rabbit antibody in 1% horse 
serum/PBS-T was used as secondary antibody for 30 min at room temperature and 
staining procedure was subsequently amplified by the A/B-complex (Vectastain Elite 
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ABC kit) for 30 min at room temperature. Immunoreactions were visualized with 3,3-
diaminobenzidine, followed by counterstaining with hematoxylin. Tumor-infiltrating 
lymphocytes, muscle cells, and normal colonic epithelia served as positive controls. 
6.5.2 Microdissection of Hemalaun- and Eosin- stained tissues 
For morphological assessment of FFPE samples and separate microdissection of 
normal and tumor tissue, slides were stained with hemalaun and Eosin (H&E 
staining), resulting in blue staining of acidic structures such as cell nuclei and red 
staining of eosinophilic structures such as the cytoplasm. Regional microdissection 
was performed to isolate normal or tumor tissue. Whole tumor areas were 
microdissected using the H&E staining, but for a protein-specific microdissection, 
tumor tissues were stained with an appropriate antibody and these brown stained 
areas were microdissected. First, normal control tissue was isolated by use of a 0.9 x 
40 mm needle pre-wetted with ATL buffer (DNeasy Blood & Tissue kit, Qiagen) and 
under a stereomicroscope. In the second step, tumor tissue was removed from the 
slide using a fresh needle. The removed tissue was collected in 180 μl of ATL buffer 
in 1.5 ml reaction tubes. 12 μl of Protease K were added to each tube and the 
samples were incubated at 56°C on a thermomixer over night. On the next day 
genomic DNA was isolated according to the manufacturer`s instructions. 
6.5 Database analysis 
Three databases and four filters were used for candidate gene selection (Fig. 3.1A). 
Information about ER/Golgi resident proteins was retrieved from the LOCATE 
database (http://locate.imb.uq.edu.au/), whose XML source was downloaded (version 
human_v3_20070620) and prepared for local usage as a MySQL database. Protein 
subcellular localization in LOCATE v3 was defined by 463 GO terms, of which 30 GO 
terms were related to ER/Golgi subcellular localization (Filter 1). From this candidate 
subset, the MNR_ensembl database (http://www.seltarbase.org/?topic= 
MNR_ensembl; version 45.36 g) allowed further specification of candidate genes by 
restriction of cMNR lengths to a minimum of seven repeat units (Filter 2). Subsequent 
exclusion of all cMNRs previously investigated revealed a list of 431 candidate genes 
(Filter 3; SelTarbase, 4th release 200707). Final selection by annotation of genes 
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encoding proteins of the cellular glycosylation/deglycosylation and glyoprotein 
transport system led to 28 genes that were used for subsequent analyses (Filter 4). 
Automated primer design was performed by a perl script using primer3_core 
(Primer3 version 0.1; http://primer3.sourceforge.net/) in combination with a self-
constructed human mispriming repeat library (see Tab. 5.5.1). The bioinformatics-
based approach is outlined schematically in Fig. 3.1.A. 
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8. Appendix 
8.1 Abbrevations 
APC Adenomatous Polyposis Coli 
Asp Asparagine 
B4GALT1 Beta-1,4-Galactosyltransferase 
BAX Bcl-2 Associated X-Protein 
BRAF V-raf murine sarcoma viral oncogene homolog B1 
cMNR Coding Mononucleotide Repeat Mutations 
cMS Coding Microsatellite 
CR Calreticulin 
CRC Colorectal Cancer 
CS Chondroitin Sulfate 
CX Calnexin 
DS Dermatan Sulfate 
ECM Extracellular Matrix 
ER Endoplasmic Reticulum 
ERAD ER associated degradation 
FGF2 Fibroblast Growth Factor Receptor 2 
FGFR3 Fibroblast Growth Factor Receptor 3 
Fuc Fucose 
GAG Glycosaminoglycan 
Gal Galactose 
GalNAc N-Acetylgalactosamine 
GALNT5 N-Acetylgalactosaminyltransferase 5 
Glc Glucose 
GlcA Glucoronic Acid 
GlcNAc N-Acetylglucosamine 
HNPCC Hereditary Non-Polyposis Colon Cancer 
HS Heparan Sulfate 
IdoA Iduronic Acid 
KS Keratan Sulfate 
LDS Lithium Dodecyl Sulfate 
Man Mannose 
MAPK mitogen-activated protein kinase 
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MCFD2 Multiple Coagulation Factor Deficiency Protein 2 
MLH1 MutL homolog 1 
MMR Mismatch Repair 
MSH2 MutS homolog 2 
MSH6 MutS homolog 6 
MSI Microsatellite Instability 
NMD Nonsense-mediated mRNA decay 
NE  Neutrophil Elastase 
NeuAc N-Acetyl-Neuraminic Acid (Sialic Acid) 
PDGF Platelet Derived Growth Factor 
PDGFR Platelet Derived Growth Factor Receptor 
PG Proteoglycan 
PLR3 Phosphatase Of Regenerating Liver-3 
PMF Post-Mitochondrial Fraction 
PMS2  
PMS Post-Meiotic Segregation 
Ser Serine 
SIAT4B Sialyltransferase 4B 
SUMF1 Sulfatase Modifying Factor 1  
TGFBR Transforming Growth Factor Beta Receptor 
TGFß Transforming Growth Factor 
Thr Threonin 
VEGF Vascular Endothelial Growth Factor 
Xyl Xylose 
XYLT Xylosyltransferase 
8.2 Own publications, presentations and posters 
Original Papers 
Roeckel N, Woerner SM, Kloor M, Yuan YP, Patsos G, Gromes R, Kopitz J, Gebert 
J. (2009) High frequency of LMAN1 abnormalities in colorectal tumors with 
microsatellite instability. Cancer Res 69:292-299. 
Patsos G, André S, Roeckel N, Gromes R, Gebert J, Kopitz J, Gabius HJ. 
Compensation of loss of protein function in microsatellite-unstable colon cancer cells 
(HCT116): a gene-dependent effect on the cell surface glycan profile. (2009) 
Glycobiology. 19:726-734 
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Roeckel N, Weber A, Gromes R, Himmelsbach S, Kopitz J, Gebert J. (2010). XYLT2, 
a glycosyltransferase as a target in MSI-H tumorigenesis. In preperation. 
Poster presentation 
Roeckel N, Woerner SM, Kloor M, Patsos G, Gromes R, Karl M, Kopitz J, Gebert J. 
Mutational inactivation of glycoprotein transporter (LMAN1) in MSI colorectal 
adenomas and carcinomas. International society for gastrointestinal hereditary 
tumours (InSiGHT), poster presentation, 24. – 27.06.2009, Düssedorf. 
Oral presentation 
Roeckel N, Woerner SM, Kloor M, Yuan YP, Patsos G, Gromes R, Karl M, Kopitz J, 
Gebert J. Loss of LMAN1 glycoprotein carrier function in microsatellite unstable 
colorectal tumors. American Association of Cancer Research (AACR) Annual 
Meeting, minisymposium session, oral presentation, 18.- 22.04.2009, Denver, 
Colorado, USA.  
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